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ABSTRACT 
Vav proteins are phosphorylation-dependent guanine nucleotide exchange factors that catalyze 
the activation of members of the Rho family of guanosine triphosphatases (GTPases). The 
current regulatory model holds that the non-phosphorylated, catalytically inactive state of Vav 
proteins is maintained by intramolecular interactions among the N-terminal domains and the 
central catalytic core, which block the binding of Vav proteins to GTPases. Here, we showed that 
this autoinhibition is mechanistically more complex, because it also involves the bivalent 
association of the C-terminal Src homology 3 (SH3) region of Vav with its catalytic and 
pleckstrin homology (PH) domains. Such interactions occurred through noncanonical, proline-
rich region-independent mechanisms. Full release from this double-locked state required 
synergistic weakening effects from multiple phosphorylated tyrosine residues, thus providing an 
optimized system to generate gradients of Vav activity depending on upstream signaling inputs. 
This mechanism is shared by mammalian and Drosophila melanogaster Vav proteins, suggesting 
that it may be a common regulatory feature for this protein family. 
 INTRODUCTION 
The Vav family is a group of tyrosine phosphorylation-dependent guanine nucleotide exchange 
factors (GEFs) that activate members of the Rac and Rho families of guanosine triphosphatases 
(GTPases) downstream of protein tyrosine kinases (1-8). This family consists of single proteins 
in invertebrates and three members in most vertebrate species (Vav1, Vav2, and Vav3) (4, 5). 
Genetic analyses have demonstrated that these proteins play critical functions in many biological 
responses, including lymphopoiesis (3, 9), osteogenesis (10), cardiovascular homeostasis (11-
14), neuronal-related processes (13, 15-17), and tissue rhythmic behaviors in nematodes (18). 
Vav family proteins are also involved in human pathologies, such as cancer (19-24), metabolic-
related diseases (25), multiple sclerosis (26), immune-related deficiencies (26), and the life cycle 
of pathogens inside eukaryotic host cells (4). 
 
Vav proteins are characterized by the presence of a complex array of structural domains (Fig. 
1A). These include a calponin-homology (CH) domain and an acidic (Ac) region with three 
regulatory phosphorylation sites (Tyr142, Tyr160, and Tyr174 in the case of Vav1) (27); central Dbl 
homology (DH), pleckstrin homology (PH), and C1 type zinc finger (ZF) domains that fold 
together to form the active catalytic core (7, 28-30); as well as a C-terminal arrangement of 
either Src homology 2 (SH2)-SH3 domains (in invertebrates) or SH3-SH2-SH3 domains (in 
organisms from pro-chordates to mammals) (5). The noncatalytic domains exert pleiotropic roles 
during signal transduction, which contribute to the intramolecular regulation of Vav proteins, the 
phosphorylation step, and engagement of GTPase-independent routes (4). These roles are not 
mutually exclusive because, for example, the CH region inhibits the catalytic activity of Vav in 
cis (6, 7, 31) and, at the same time, plays effector roles that favor the engagement of Ca2+-
dependent routes that stimulate nuclear factor of activated T cells (NFAT) (32), a transcriptional 
factor involved in lymphocyte proliferation (33). Similarly, the most C-terminal SH3 domain 
(referred to hereafter as the CSH3 domain) interacts with proline-rich region (PRR)-containing 
proteins that favor downstream signaling and, in the case of T lymphocytes, the optimal 
phosphorylation of Vav proteins in response to activation of the T cell receptor (TCR) (4, 5, 34). 
 
According to the current regulatory model, non-phosphorylated Vav proteins are catalytically 
inactive because of the physical occlusion of the GTPase-binding site in the DH domain by the 
CH-Ac region (31) (fig. S1A). This closed, autoinhibited structure is stabilized by interactions 
between the Tyr174 hydroxyl group and the GTPase-binding region of the DH domain, as well as 
by interdomain contacts between the CH domain with the DH-PH region (31) (fig. S1B). Upon 
cell stimulation, the phosphorylation of the three tyrosines located in the Ac region eliminates 
these inhibitory interactions, which leads to exposure of the catalytic site, binding to the GTPase, 
and the ensuing catalytic step (fig. S1A) (31). Consistent with this model, mutations that disrupt 
such an autoinhibitory structure result in proteins with constitutive, phosphorylation-independent 
catalytic activity both in vitro and in cells (fig. S1A) (6, 7, 27, 28, 31). 
 
It is still uncertain, however, whether this model alone can fully explain the regulation of Vav 
activity. For example, we observed that Vav1Y174F, a mutant protein that lacks the main inhibitory 
tyrosine residue, still requires tyrosine phosphorylation to become catalytically active in vitro 
(27). We also reported that the compound mutation of the three tyrosine residues of the Ac 
region does not recapitulate the activation effect derived from the deletion of the CH domain in 
Vav proteins (27, 28), thus suggesting that the autoinhibited structure can be stabilized by 
additional interactions outside the Ac region. Finally, Vav proteins have additional 
phosphorylatable residues outside of the Ac region (27), suggesting that further phosphorylation-
dependent steps may contribute to fine-tune the regulation of these proteins during signal 
transduction. Consistent with these ideas, we report here that optimal autoinhibition of Vav 
proteins requires cooperative intramolecular interactions mediated by the CSH3 domain. This 
mechanism provides a multilayered safety control system to avoid spurious activation of these 
proteins by signaling noise and, at the same time, a potential way to modulate the signaling 
competence of Vav proteins depending on either the strength or duration of extracellular stimuli. 
 
RESULTS 
The CSH3 domain participates in the inhibition of Vav family proteins 
During the course of experiments aimed at establishing the regulatory role of the C-terminus of 
Vav1, we generated a 10 amino acid-long deletion mutant that disrupted the folding of the Vav1 
CSH3 domain (Vav1Δ835-845; Fig. 1A). Given the important role of Vav1 in lymphocyte signaling 
(3-5, 9), we first tested the biological activity of this mutant in Jurkat cells (a human CD4+ T cell 
leukemia cell line), and we used as read-outs the Vav1-dependent activation of c-Jun N-terminal 
kinase (JNK), F-actin polymerization, and NFAT. JNK and F-actin are direct downstream 
elements of the Vav1-Rac1 pathway and therefore were used as surrogate read-outs for Vav1 
catalytic activity in cells (Fig. 1B). In contrast, NFAT requires multiple signaling inputs for its 
activation, including signals dependent on the Vav1 CH domain, phospholipase C-γ (PLC-γ)-
dependent Ca2+ signaling, and synergistic cross-talk with other TCR-activated pathways (Fig. 
1B) (9, 32, 35). As controls for these experiments, we used wild-type Vav1 (referred hereafter as 
Vav1WT) and the Vav1Δ1-186 and Vav1Y174F mutant proteins (Fig. 1A). Vav1Δ1-186 displays 
phosphorylation-independent GEF activity because of the elimination of the inhibitory N-
terminal domains (Fig. 1A) (6, 7, 28); however, it cannot stimulate NFAT because of the lack of 
the N-terminal CH domain (Fig. 1B) (28, 32). As mentioned earlier, the Vav1Y174F mutant 
exhibits increased activity in some assays; however, unlike Vav1Δ1-186, it still requires 
phosphorylation steps to become fully activated in vitro and in cells (27). 
 
Because previous data demonstrated that the interaction of the Vav1 CSH3 domain with PRR-
binding proteins was required for the biological activity of Vav1 in most cell types (28, 34, 36, 
37), we expected that the CSH3-deficient Vav1Δ835-845 mutant would exhibit less activity than that 
of its wild-type counterpart; however, we unexpectedly found that Vav1Δ835-845 was as hyperactive 
as was Vav1Δ1-186 in experiments measuring the activation of JNK (Fig. 1, C to F) and F-actin 
polymerization (Fig. 1G). This increased activity was quite similar in non-stimulated and TCR-
stimulated Jurkat cells (Fig. 1, C to F), indicating that this mutant protein had become 
phosphorylation-independent. Consistent with this, we observed that Vav1Δ835-845 and Vav1Δ1-186, 
but not Vav1WT, were similarly active in wild-type and TCR-deficient Jurkat cells (Fig. 1, C and 
D). Vav1Δ835-845, unlike the N-terminally truncated Vav1 proteins (28, 32), also showed enhanced 
activity when tested in NFAT activity assays (Fig. 1, H and I); however, this biological response 
still required the engagement of the TCR to achieve maximal stimulation (Fig. 1, H and I). We 
observed similar results in experiments in which chicken DT40 B cells were transiently 
transfected with plasmid encoding Vav1Δ835-845 (Fig. 1, H and I), which indicated that the 
increased activity of this C-terminally truncated Vav1 protein was conserved in both T cell and B 
cell lines. 
 Vav1Δ835-845 also showed higher biological activity than that of Vav1WT in assays of JNK activity 
and F-actin polymerization in non-hematopoietic COS1 cells; however, unlike in lymphocytes, 
the activity of Vav1Δ835-845 was substantially reduced compared to that of Vav1Δ1-186 (Fig. 2, A and 
B; fig. S2A) and Vav1Y3xF (fig. S2A), a mutant Vav1 in which the three inhibitory tyrosine 
residues of the Ac region are mutated to phenylalanines (Fig. 1A) (27). Furthermore, unlike the 
conventional Vav1Δ1-186 and Vav1Y3xF mutant proteins (6, 27, 28), Vav1Δ835-845 did not exhibit 
oncogenic activity when tested in focus-formation assays (Fig. 2C). The reduced activity of 
Vav1Δ835-845 in COS1 and NIH3T3 cells was probably a result of the loss of CSH3-dependent 
effector functions, because the Vav1Y3xF protein also lost its transforming activity (27, 28) when 
it lacked the C-terminal amino acid residues 835 to 845 (Fig. 2C). This deletion also induced the 
constitutive activation of Vav2, Vav3 (Fig. 2, D and E), and Drosophila Vav (Fig. 2, A and B), 
indicating that the inhibitory role exerted by this domain may be common to all Vav family 
members. Despite this, the C-terminal truncation did not change the specific signaling output 
induced by each Vav family member in cells. For example, we observed that Vav2Δ860-868 
stimulated NFAT in B cells, but not in T cells, a cell type specificity also shared by Vav2WT (fig. 
S2, B and C) (38). Together, these results suggest that the CSH3 domains of Vav family 
members exert a hitherto unknown inhibitory role that may have arisen very early on in the 
evolutionary history of this GEF subgroup. Moreover, these results suggest that the relative 
contribution of the negative and positive roles of the CSH3 domain to the biological activity of 
these proteins is highly dependent on the cell type and biological response involved. 
 
The CSH3 domain inhibits the catalytic activity of Vav proteins 
To investigate whether the enhanced biological activity of CSH3-deficient Vav proteins was a 
consequence of increased catalytic activity, we isolated hexahistidine (6xHis)-tagged variants of 
Vav1WT, Vav1Δ835-845, Vav3WT, and Vav3Δ841-847 from baculovirus-infected Sf9 insect cells (Fig. 3A) 
and subsequently tested them in vitro in GDP-GTP exchange assays. As a negative control, we 
used a 6xHis-Vav3 protein fragment that contains only the DH-PH region (Vav3DH-PH, Fig. 3A). 
We showed previously that this protein is catalytically inactive because of the absence of the ZF 
region (7). As a positive control, we used the 6xHis-DH-PH region of a RhoA- and Cdc42-
specific GEF (human Dbs), which was provided by the commercial kit used to assay GDP-GTP 
exchange. With this approach, we observed that 6xHis-Vav1WT was catalytically inactive on all 
of the GTPases tested (Fig. 3, B to D); however, as expected (8, 27, 28), 6xHis-Vav1WT became 
catalytically active upon in vitro phosphorylation by the protein tyrosine kinase Lck (Fig. 3, E 
and F). In contrast, 6xHis-Vav1Δ835-845 exhibited phosphorylation-independent GDP-GTP 
exchange activity on both Rac1 (Fig. 3B) and RhoA (Fig. 3C). This activity was proportional to 
the amount of input protein used in the assays (Fig. 3, B and C). Vav1Δ835-845 did not elicit any 
detectable nucleotide exchange activity on Cdc42 (Fig. 3D), as was previously described for 
other Vav1 variants (8). Dbs showed the opposite catalytic specificity, being primarily active on 
RhoA (Fig. 3C) and Cdc42 (Fig. 3D), whereas it displayed much lower activity on Rac1 (Fig. 
3A). 
 
Parallel experiments indicated that 6xHis-Vav3Δ841-847 had constitutive, phosphorylation-
independent exchange activity towards Rac1 (Fig. 3G) and, to a lesser extent, RhoA (Fig. 3H). 
Similar to its Vav1 mutant counterpart, 6xHis-Vav3Δ841-847 did not show activity on Cdc42 (Fig. 
3I). The catalytic activity of this mutant protein was comparable to that shown by the previously 
described constitutively active Vav3Δ1-144 protein (Fig. 3G) (7). Confirming the specificity of 
these reactions, we did not observe any exchange activity when the purified 6xHis-Vav3 DH-PH 
region was tested (Fig. 3G) (7). These results indicate that Vav1 and Vav3 acquire constitutive 
GDP-GTP exchange activity upon the elimination of the most distal amino acids of their 
respective CSH3 domains. Corroborating these in vitro results, we found that Vav1Δ1-186 and 
Vav1Δ835-845, but not Vav1WT, ectopically expressed in COS1 cell lysates interacted with 
bacterially expressed glutathione-S-transferase (GST)-fused Rac1G15A (GST-Rac1G15A) and GST-
RhoAG17A proteins in standard pull-down assays (Fig. 3J). These results provided further 
evidence for the exposure of the Vav1 catalytic site upon the removal of the CSH3 domain, 
because these GTPase mutants interact with active forms of upstream GEFs because of their 
nucleotide-free state (39). Finally, with GTPase-linked immunosorbent assays, we demonstrated 
that the CSH3-depleted mutants of both Vav1 and DmVav promoted the activation of 
endogenous Rac1 when ectopically expressed in COS1 cells (Fig. 3, K and L). Such activity was 
very similar to that shown by the constitutively active Vav1Δ1-186 mutant protein (Fig. 3, K and L). 
As expected, the full-length Vav1 and DmVav proteins were inactive in these assays (Fig. 3, K 
and L). These results indicate that the CSH3 domain contributes to the regulation of both the 
catalytic and biological activities of Vav family proteins, possibly through an inhibitory 
intramolecular mechanism similar to that exerted by the N-terminal CH domain and Ac region. 
 
The CSH3 domain inhibits Vav1 activity in cis 
To elucidate the inhibitory role of the CSH3 domain, we first investigated whether it could be 
mediated by a canonical interaction with PRRs. Arguing against this possibility, we observed 
that the inactivation of the PRR-binding site of the Vav1 CSH3 domain (through the introduction 
of the P833L mutation) did not induce the activation of full-length Vav1 (Fig. 4, A and B). This 
result was consistent with previous experimental data (4, 5, 34). These observations led us to 
investigate whether the CSH3 domain inhibited Vav1 through a PRR-independent mechanism in 
cis To this end, we performed GST-based pull-down experiments to detect possible interactions 
of the wild-type (GST-CSH3WT) and the P833L mutant (GST-CSH3P833L) versions of the Vav1 
CSH3 domain with Vav1 proteins ectopically expressed in COS1 cells. Because we surmised 
that access to the putative CSH3-binding site of Vav1WT could be blocked by the interaction of 
its own CSH3 (Fig. 4C), we decided to include in these experiments the mutants Vav1Δ835-845 and 
Vav1Δ1-186. Based on earlier results (Figs. 1 to 3), we expected that the CSH3-binding site of 
Vav1Δ835-845 would be fully exposed and, therefore, that this mutant would serve as a good 
positive control for these experiments (Fig. 4C). On the other hand, the use of the Vav1Δ1-186 
mutant enabled us to check whether the strength of the intramolecular CSH3-Vav1 interaction 
could be influenced by the previously described CH domain and Ac region–dependent 
conformational changes associated with the catalytic activation of Vav proteins (29-31). 
 
We found that GST-CSH3WT physically interacted with Vav1Δ835-845, but not with Vav1WT or 
Vav1Δ1-186 (Fig. 4D), indicating that the truncation of the CSH3 domain was required to fully 
expose its intramolecular binding site. The GST-CSH3P833L protein consistently showed better 
interactions with Vav1Δ835-845 than did the GST-CSH3WT bait (Fig. 4D), thus corroborating the 
idea that this intramolecular inhibitory mechanism is mediated by a non-canonical, PRR-
independent mechanism. Furthermore, the GST-CSH3P833L bait also showed weaker, but 
reproducible, binding to Vav1WT and, to a larger extent, to Vav1Δ1-186 (Fig. 4D). All of these 
interactions were specific, because the non-chimeric GST protein did not interact with any of the 
Vav1 proteins used in these experiments (Fig. 4D). These interactions were also highly selective, 
as demonstrated by the lack of efficient binding of the GST-CSH3P833L bait to other C-terminally 
truncated Vav family proteins (Fig. 4E). Together, these results suggest that the stability of the 
intramolecular CSH3-Vav1 interaction is stronger when Vav1 is in the non-active state, is 
partially destabilized upon the release of the inhibitory N-terminal regions (Vav1Δ1-186), and is 
totally disrupted when the CSH3 is truncated (Vav1Δ835-845). Furthermore, these results suggest 
that the binding of PRR-containing proteins to the canonical PRR-binding site of CSH3 might 
indirectly disrupt the interaction between CSH3 and Vav1. 
 
The CSH3 domain binds to the DH-PH region of Vav1 
The interaction of the GST-CSH3P833L bait with both Vav1Δ1-186 and Vav1Δ835-845 that we observed 
in the earlier experiments indicated that the internal CSH3-binding site must lie outside the CH-
Ac and CSH3 regions. The use of additional mutant proteins also excluded the possibility that 
the binding site could be located in the PRR-NSH3 region of Vav1 (fig. S3), thus suggesting that 
the interaction was likely to take place within the catalytic DH-PH-ZF cassette. To test this 
possibility, we investigated the interaction of the GST-CSH3P833L bait with different 
combinations of the domains present in that cassette in pull-down experiments (Fig. 4F). To 
facilitate these experiments, we expressed these regions in COS1 cells as fusions with enhanced 
green fluorescent fusion protein (EGFP). We observed that GST-CSH3P833L interacted with 
EGFPs containing the DH (EGFP-DH-PH-ZF, EGFP-DH-NPH, and EGFP-DH) and PH (EGFP-
DH-PH-ZF and EGFP-PH) domains of Vav1 (Fig. 4, G and H; fig. S4A); however, it did not 
associate with the isolated ZF domain (Fig. 4G) or the α6 helix of the DH domain (fig. S4A). 
Furthermore, the ZF domain seemed to constrain the interaction of the Vav1 CSH3 domain with 
its targets, because the EGFP-DH-NPH and EGFP-PH constructs showed better binding to the 
GST-CSH3P833L bait in these experiments than did the EGFP-DH-PH-ZF construct (Fig. 4G and 
fig S4A). Furthermore, the DH region showed a better association to the bait when the DH 
region was attached to the NPH fragment (Fig. 4H). These results suggest that the CSH3 domain 
probably has two independent docking sites within the DH-α6-PH region and, in addition, that 
the stability of such interactions may be influenced by conformational fluctuations imposed by 
the intervening α6 helix and the adjacent ZF region. 
 
Additional pull-down experiments indicated that the ectopically expressed EGFP-Vav1 DH-PH-
ZF cassette interacted more efficiently with GST-CSH3P833L than with other known interacting 
partners, such as the downstream GTPases and the inhibitory N-terminal CH region (fig. S4B). 
Confirming that the interaction between the CSH3 domain and the DH-PH-ZF region of Vav1 
did not require the participation of other proteins present in the COS1 cell lysates used in the 
pull-down experiments, we found with purified proteins (Fig. 4I) and surface plasmon resonance 
techniques that a bacterially expressed Vav1 DH-PH-ZF region fused to the maltose binding 
protein (MBP) associated with the filter-immobilized GST-CSH3WT bait (Fig. 4J). As a negative 
control, MBP fused to β-galactosidase (Fig. 4I) showed no detectable interaction with the GST-
CSH3WT bait (Fig. 4J). 
 
To further support these observations, we performed electron microscopy (EM) experiments to 
obtain a low-resolution image of the unphosphorylated 6xHis-Vav1Δ1-144 mutant. This protein 
lacks the inhibitory CH domain and, similar to Vav1Δ1-186, shows constitutive, phosphorylation-
independent activity (7, 28). Although EM analysis does not yield data at atomic resolution, it 
can provide useful information about the shape and volume of proteins under analysis, as well as 
the stereo-spatial distribution of structural domains within these volumes. The analysis of 
purified fractions of 6xHis-Vav1Δ1-144 (fig. S5A) revealed that 6xHis-Vav1Δ1-144 displayed a 
homogenous structure characterized by the presence of a bulky area (referred to as the “head”) 
and an elongated extension (designated as the “tail”) (fig. S5B). Images derived from different 
rotated views of the molecule along its axis were collected (fig. S5C) and processed to generate 
an average three-dimensional (3D) reconstruction with an overall resolution of ≈32.5 Å (fig. 
S5D). 
 
We next used in silico docking methods to define the stereo-spatial distribution of the DH-PH-
ZF and SH3-SH2-SH3 regions within the EM-generated volume. Because the structure of the 
Vav1 C-terminus is unknown, we used the available crystal structure of Grb2 (40), an adaptor 
protein with a Vav1-like arrangement of SH2 and SH3 domains, to model docking. These 
methods assigned the catalytic DH-PH-ZF core to the head region of 6xHis-Vav1Δ1-144 (fig. S5D). 
Although the limited resolution of the EM structure prevented us from performing an unbiased 
modeling, the flat shape of this area and its connectivity to the C-terminal tail favored certain 
orientations of the DH-PH-ZF cassette (fig. S5D). The SH2 domain and one of the two SH3 
domains of Grb2 could be fitted within the tail of 6xHis-Vav1Δ1-144 without any deviation from 
their localization within the crystal structure of Grb2 (fig. S5D). In contrast, the second SH3 
region of Grb2 required a substantial clockwise rotation towards the head region to be fully 
accommodated within the density of 6xHis-Vav1Δ1-144 (fig. S5D). Such movement is structurally 
possible, because previous results have shown that Grb2 adopts multiple conformational states 
because of the flexibility of its interdomain linker regions (41). Consistent with our biochemical 
data, this rotation placed the SH3 domain in close proximity to the PH domain and the C-
terminal side of the DH domain, including the α6 helix, of Vav1 (fig. S5D). This location is also 
in the vicinity of the docking site of the CH domain and part of the Ac region when Vav1 is in 
the non-phosphorylated, inactive conformation (31). However, unlike the case of the CH region, 
the presence of the CSH3 domain in that location should not interfere with the GEF activity of 
Vav1, because we previously showed that the 6xHis-tagged Vav1Δ1-144 and Vav3Δ1-144 oncoproteins 
have phosphorylation-independent GEF activity in vitro (7, 28). 
 
The DH domain α6 helix stabilizes the inhibitory CSH3-Vav1 interaction 
To gain further information about this previously uncharacterized regulatory mechanism, we first 
focused our attention on the DH domain α6 helix (Fig. 5A). This region was of interest because 
its integrity was clearly important for the interaction between the CSH3 domain and the DH-PH 
region that we detected in pull-down experiments (Fig. 4, G and H; fig. S4A). Furthermore, the 
DH α6 helix undergoes large topological changes during the activation step of Vav proteins (fig. 
S6) (29-31). We hypothesized that if residues of the α6 helix were important for the stability of 
the intramolecular CSH3-Vav1 interaction, then their mutation in Vav1Δ835-845 would result in the 
loss of interaction with the GST-CSH3 fusion protein in pull-down experiments. 
 
We chose the residues to be mutated based on evolutionary conservation criteria, their 
localization in areas undergoing topological changes between the inactive and active catalytic 
states of Vav1 (fig. S6), and by their being present in all of the EGFP-Vav1 fragments that we 
found could bind to the CSH3 region (Fig. 5A). As a control, we mutated two less-conserved 
residues (Thr384 and Leu388), which are located further downstream in the DH domain α6 helix 
(Fig. 5A). We mutated the chosen residues to alanines to avoid major conformational changes 
(42). Our analysis of a first collection of DH α6 Vav1Δ835-845 mutants indicated that the amino 
acid pairs of Val373 and Lys374 and Arg375 and Asp376 were indeed important for the binding of 
both the GST-Vav1 CSH3WT and GST-Vav1 CSH3P833L proteins to Vav1Δ835-845 (Fig. 5B). By 
contrast, the residues Asn371, Glu372, Thr384, and Leu388 were dispensable for such an interaction 
(Fig. 5B, left panels). The two residues Val373 and Lys374 favored in a concerted manner the 
interaction of the Vav1 CSH3, because their single mutation was not sufficient to eliminate the 
interaction between Vav1Δ835-845 and GST-Vav1 CSH3 (Fig. 5B, right panels). In contrast, the 
Asp376 residue of the Arg375Asp376 pair was the key one that contributed to the interaction (Fig. 
5B, right panels). Some of the residues identified in these experiments seem to have pleiotropic 
roles, because Lys374 and Asp376 participate in interactions with the switch II regions of Rac1 and 
with the PH-ZF region of Vav1, respectively (fig. S6B) (29, 30). However, this is not a general 
feature of this interaction, because mutation of other residues involved in the Vav1-Rac1 
association, such as Asn371 and Arg375 (fig. S6B), did not impair the binding of Vav1Δ835-845 to the 
GST-CSH3P833L fusion protein (Fig. 5B). 
 
We next analyzed the biological activity of the Vav1D376A mutant to confirm its involvement in 
the CSH3-dependent inhibitory mechanism. We assumed that if this residue contributed to Vav1 
autoinhibition, its mutation would release the CSH3 domain from its binding site and, therefore, 
would result in the enhanced activation of the full-length protein in cells. If so, such data could 
also contribute to ruling out the possibility that the disruption of the interaction between GST-
CSH3P833L and Vav1Δ835-845 that we observed earlier (Fig. 5B) might be because of spurious effects 
of the D376A mutation in the overall Vav1 structure. Confirming our pull-down data, we 
observed that Vav1D376A, but not Vav1K374A, displayed increased biological activity compared to 
that of Vav1WT in both JNK and NFAT assays (Fig. 5, C and D). Similarly, we observed that the 
D376A mutation led to an increase in the binding of the full-length Vav1 protein to the target 
GTPase Rac1 (Fig. 5E). These results indicate that specific residues within the C-terminal α6 
helix of the DH domain of Vav1, a region that undergoes a large rotation and displacement 
during Vav1 activation (fig. S6), contribute to the stabilization of the interaction between the 
CSH3 domain and the central domains of Vav1. However, this is not mediated by direct 
interactions, because the α6 helix of Vav1 alone did not bind to the CSH3 domain (fig. S4A). 
 
Residues at the RT loop and the C-terminal end of the CSH3 domain are involved in the 
inhibition of Vav1 
To identify the CSH3 residues involved in the intramolecular CSH3-Vav1 interaction, we 
assumed that their single or compound mutation into alanine residues would release this 
interaction and, therefore, make the intramolecular binding site of the CSH3 domain accessible 
to the GST-CSH3 bait proteins used in our pull-down experiments. A first round of pull-down 
experiments ruled out the individual involvement of 23 surface-exposed CSH3 residues (fig. S7, 
A and B), although the point mutation of two of these (Vav1D792A and Vav1V837A) very slightly 
increased the extent of the interaction between full-length Vav1 and the GST-Vav1 CSH3P833L 
bait (fig. S7B). The subsequent generation of compound mutations of Asp792, Phe793, and Cys794; 
Asp792, Phe793, Cys794-x, and Arg796; as well as Tyr836, Val837, Glu838, Glu839, and Asp840 around 
those sites, which are referred to as DFCmut, DFC-Rmut, and YVEEDmut, respectively (Fig. 
6A), revealed that mutations affecting the DFC-R and YVEED patches did promote increased 
binding of the respective mutant proteins to the GST-CSH3P833L bait (Fig. 6B, left panels). When 
taking into consideration the abundance of each mutant protein in the COS1 cell lysates used in 
these pull-down experiments (Fig. 6B, bottom panel on the left), we observed that the DFCmut 
had a slightly stronger effect in favoring the opening of the full-length Vav1 protein than the 
YVEEDmut (Fig. 6B, top panel, compare lanes 3 and 5). The combined mutation of the DFC-R 
patch and the YVEED region did not further increase the extent of binding of the mutant proteins 
to the bait (Fig. 6B, top panel on the left; compare lanes 4 and 6). These results indicate that 
these two sites of the CSH3 domain contribute to the formation of the autoinhibited state of full-
length Vav1 protein. 
 
Confirming the involvement of the DH domain α6 helix in these interactions, we observed that 
the compound Vav1D376A+DFC-Rmut mutant protein interacted very poorly with the GST-CSH3P833L 
fusion protein (Fig. 6B, right panels). Experiments with transfected Jurkat cells indicated that the 
Vav1DFC-R+YVEEDmut protein induced the TCR-independent stimulation of JNK activity (Fig. 6, C 
and D) and F-actin polymerization (Fig. 6E), similarly to Vav1Δ835-845 and Vav1D376A. The Vav1DFC-
R+YVEEDmut protein also enhanced basal NFAT activity, a response that was further increased upon 
TCR stimulation (fig. S8, A and B). The combined DFC-R+YVEED and D376A mutations did 
not increase the biological activity already displayed by the Vav1DFC-R+YVEEDmut and Vav1D376A 
proteins (Fig. 6, C and D; fig. S8, A and B), indicating that all of those residues functioned 
redundantly in the regulation of Vav1 activity. 
 
We obtained similar results when we tested these proteins in COS1 cells with JNK activity 
assays (fig. S8, C and D) and GST-Rac1G15A–binding experiments (fig. S8E). The cooperative 
action of the CSH3 DFC-R and YVEED residues was required to fully inhibit Vav1 in cells, as 
evidenced by the lower biological activity shown by Vav1DFC-Rmut and Vav1YVEEDmut proteins in 
cells when compared to that shown by Vav1DFC-R+YVEEDmut (Fig. 6, F and G). However, we found 
that Vav1DFC-Rmut showed increased basal activity compared to that of Vav1WT (Fig. 6, F and G), 
indicating that the DFC-R motif contributes more substantially to the stabilization of the 
autoinhibited state of Vav1 than does the YVEED motif when tested in cells. Ruling out the 
possibility that the activation of the Vav1D376A+DFC-Rmut mutant might be a result of the deleterious 
effects of the mutations in the overall folding of the CSH3 domain, we demonstrated that a Vav1 
CSH3 domain that had mutations in the DFC-R, YVEED, and DFC-R+YVEED regions could 
still efficiently bind to the heterogeneous ribonucleoprotein K (hnRNPK), a protein that interacts 
with the Vav1 CSH3 domain through a canonical, PRR-based interaction (fig. S8F) (43, 44). As 
a control, we found that the interaction between hnRNPK and the CSH3 domain was abolished 
when the PRR-binding site of CSH3 was inactivated by the incorporation of the P833L mutation 
(fig. S8F) (43, 44). 
 
The large spatial distribution of the Vav1 CSH3 domain residues involved in the inhibition of the 
full-length protein led us to investigate the possibility that the DFC and YVEED motifs might be 
involved in the recognition of independent regions of the catalytic DH-PH-ZF core, an idea that 
is also consistent with our earlier observations that indicate that the Vav1 CSH3 domain binds to 
both the isolated DH and PH regions of Vav1 (Fig. 4, G and H; fig. S4A). To evaluate this 
possibility, we investigated the binding of the GST-CSH3DFC-Rmut+P833L, GST-CSH3P833L+YVEEDmut, 
and GST-CSH3DFC-Rmut+P833L+YVEEDmut fusion proteins to all of the domains present in the Vav1 
catalytic core (Fig. 4F). We observed that mutation of the DFC-R region eliminated the 
interaction between the GST fusion protein and the Vav1 DH-NPH region, but not the Vav1 PH 
region (Fig. 6H). Conversely, mutation of the YVEED region abolished the interaction between 
the bait and the Vav1 PH region, but not the Vav1 DH-NPH region (Fig. 6H). As was expected 
from our previous results, compound mutations of the DFC-R and YVEED regions eliminated 
the interaction between GST-CSH3P833L and all of the ectopic proteins, including EGFP fused to 
the entire DH-PH-ZF cassette (Fig. 6H). These results indicate that the Vav1 CSH3 domain uses 
residues present in the RT-loop (DFC-R motif) and its C-terminal end (YVEED motif) to interact 
with the DH and PH regions, respectively (Fig. 6A). 
 
Multiple phosphorylation sites are involved in the activation of Vav1 in cells 
Given the close connection between Vav1 and tyrosine kinase–regulated signaling pathways (5, 
45), we decided to investigate whether the loss of the CSH3-dependent inhibitory interaction 
could be mediated by tyrosine phosphorylation–dependent events. In addition to the previously 
known phosphorylation sites at Tyr142, Tyr160, and Tyr174 (27), we found through mass 
spectrometry techniques that Vav1 was consistently phosphorylated at three additional tyrosine 
residues (Tyr541, Tyr544, and Tyr836) in TCR-stimulated Jurkat cells and EGF-stimulated COS1 
cells (table S1). Tyr541 and Tyr544 are located in the ZF domain of Vav1, and they establish bonds 
with residues present in the PH-ZF region (fig. S6B) (29, 30), whereas Tyr836 is located in the 
YVEED motif of the CSH3 domain (Fig. 6A). 
 
To confirm the proteomics data with independent techniques, we generated rabbit polyclonal 
phospho-specific antibodies against each of these residues and, in addition, to two of the 
previously known phosphorylation sites: Tyr142 and Tyr160. A phospho-specific antibody against 
the key regulatory residue Tyr174 was reported previously (27). We demonstrated the specificities 
of these antibodies through the detection of the phosphorylation of each of residues of interest in 
Vav1WT, but not in the appropriate phospho-site mutant proteins, in EGF-stimulated COS1 cells 
(fig. S9). With these antibodies, we demonstrated that endogenous Vav1 proteins became 
effectively and rapidly phosphorylated on Tyr541, Tyr544, and Tyr836 upon the TCR-dependent 
stimulation of Jurkat cells (Fig. 7A). Such phosphorylation was comparable in amplitude and 
kinetics to that shown by the three previously described N-terminal phosphorylation sites of 
Vav1: Tyr142, Tyr160, and Tyr174 (Fig. 7A). 
 
We mutated these previously uncharacterized phospho-sites into either phenylalanine or 
glutamate residues in full-length Vav1 to assess their contributions to the activation of Vav1 in 
cells. In addition, we modified these residues in the context of the Vav1Y174F mutant protein to 
detect potential synergisms with the phospho-sites involved in the release of the inhibitory N-
terminal domains. When we tested these mutants in JNK assays, we found that the effects of the 
mutations were highly contingent upon both the stimulation state and type of Vav1 protein used. 
In unstimulated Jurkat cells, the Y541F, Y544F, Y836F, and Y836E Vav1 point mutants 
displayed biological activities slightly greater than that of Vav1WT, whereas the Y836F and 
Y836E mutants had activities that were greater than those shown by both Vav1WT and Vav1Y174F 
(Fig. 7, B and C). The Vav1Y541E and Vav1Y544E mutant proteins exhibited activities similar to that 
of Vav1WT (Fig. 7, B and C), indicating that the single mutation of each of those two residues did 
not substantially affect the basal activities of these proteins. However, in Jurkat cells stimulated 
with anti-CD3 antibody, the phospho-site mutants were unexpectedly less active than were the 
Vav1WT and Vav1Y174F proteins (Fig. 7, B and C), indicating that the phosphosite mutants had 
become insensitive to upstream stimulation. A similar defect was seen in the case of Vav1P833L 
(Fig. 4A), which was probably a result of the known requirement of the canonical PRR-binding 
site of the Vav1 CSH3 domain for the optimal phosphorylation of Vav1 in lymphoid cells (34). 
A similar explanation can be used in the case of the Y833F and Y836E mutations, because these 
residues are located in the vicinity of the PRR-binding site. Consistent with this interpretation, 
the Vav1YVEEDmut protein (which contains the Y836A mutation and can bind to PRR-containing 
proteins) showed activities very similar to that of Vav1WT in TCR-stimulated cells (Fig. 6, C and 
F). 
 
In this functional context, it is possible that the lack of responsiveness of the Vav1 ZF phospho-
site mutants to TCR stimulation could be caused by conformational changes that, by restricting 
the accessibility of the PRR-binding site of the CSH3 domain to other signaling proteins, could 
inhibit phosphorylation of the protein. Consistent with this idea, we found that the concurrent 
mutation of Tyr174 restored the TCR-responsiveness of the Y544E mutant protein (Fig. 7, B and 
C). Furthermore, this mutation synergized with the rest of phospho-site mutations, which led to 
the generation of constitutively activate proteins in all cases (Fig. 7, B and C). The most marked 
effect was observed in the case of the compound Y174F,Y836E mutant protein, which displayed 
biological activities that were similar to those of the Vav1Δ1-186 and Vav1Δ835-845 mutants (compare 
Fig. 7B and Fig. 1C), but were increased compared to those of the Vav1Y174F or Vav1Y3xF mutants 
(Fig. 7, B and C). Although the Vav1Y174F+Y544E protein was not constitutively active, it enhanced 
the activation of JNK compared to that of Vav1WT under both unstimulated and stimulated 
conditions (Fig. 7, B and C). These results indicate that the full activation of Vav1 under 
physiological conditions requires the synergistic effect of multiple phosphorylation sites located 
in the Ac, ZF, and, to a much larger extent, the CSH3 regions. In addition, these results suggest 
that Vav1 can adopt different conformational or functional states depending on the specific 
tyrosine residues and domains that are phosphorylated at any given time. 
 
To establish a connection between the constitutive activation of the phospho-site mutant proteins 
and the release of the intramolecular CSH3-Vav1 interaction, we evaluated their interactions 
with the GST-CSH3P833L bait in pull-down experiments. Consistent with a partial release of such 
an inhibitory interaction, we observed that the Y174F mutation promoted the increased binding 
of full-length Vav1 to the GST-CSH3P833L bait (Fig. 7D, left panel). This effect was similar to 
that caused by truncation of the inhibitory N-terminal domains (Fig. 4D). The positive effect 
caused by the Y174F mutation was eliminated when combined with the ZF and CSH3 phospho-
site mutations (Fig. 7D, left panel), suggesting that each of these residues regulate, dependent on 
their phosphorylation states, the formation of conformational states that affect the stability of the 
intramolecular CSH3-Vav1 interaction. 
 
Ruling out the possibility that the lack of association between either of the two ZF phospho-site 
mutant proteins and the GST-CSH3P833L fusion protein was because of the re-establishment of the 
intramolecular interaction between the DH-PH-ZF region and CSH3 domain, we found that these 
mutations also abolished interactions with the GST-CSH3P833L bait when introduced into the 
CSH3-truncated Vav1Δ835-845 protein (Fig. 7D, right panel). The binding defects caused by these 
two phospho-site mutations were not because of spurious effects on the overall structure of 
Vav1, because the Vav1Y541F+Δ835-845 and Vav1Y544F+Δ835-845 mutant proteins still retained their ability 
to interact with GST-Rac1G15A (Fig. 7E). Together, these results indicate that the phosphorylation 
state of Tyr836 and, to a lesser extent, those of Tyr541 and Tyr544, contributes to the regulation of 
Vav1 activity through synergistic cross-talk with phosphosites localized with the Ac region. 
 
Discussion 
We showed that optimal autoinhibition of Vav proteins requires the coordinated interaction of 
the CH-Ac and CSH3 regions with the central catalytic core (Fig. 7F and fig. S10, point i). This 
autoinhibited structure restricts both the catalytic-dependent and -independent outputs of these 
proteins, as evidenced by the concurrent stimulation of downstream JNK and NFAT signaling 
upon disruption of the CSH3-mediated inhibition by mutagenesis techniques. Within this 
autoinhibited structure, the CH domain and Ac region seem to be primarily involved in the 
occlusion of the catalytic site, and, to a much lesser extent, in the stabilization of the 
intramolecular CSH3-Vav1 interaction (Fig. 7F and fig. S10, points ii and iii). Conversely, the 
CSH3-mediated interaction does not block the catalytic activity per se; rather, it seems to work 
as an extra safety latch for the stability of the interaction between the CH and Ac regions and the 
catalytic core. 
 
Consistent with these ideas, we showed that N-terminally deleted proteins were constitutively 
active despite maintaining the intramolecular CSH3-Vav1 interaction (fig. S10, point ii). 
Furthermore, we showed, through in vitro GDP-GTP exchange assays and assays conducted in 
TCR-deficient Jurkat cells, that elimination of CSH3-mediated inhibition led to the constitutive 
activation of Vav proteins even under conditions that did not favor the phosphorylation-
dependent release of the CH and Ac regions from the catalytic core (fig. S10, points iv and v). 
These two inhibitory inputs were eliminated by the synergistic effects of several phosphorylated 
tyrosine residues (Fig. 7F and fig. S10, point vi), thus providing a simple mechanistic framework 
to couple the kinase association step with the acquisition of full signaling competence by these 
proteins during signal transduction. Our mutagenesis experiments revealed that the activation of 
Vav proteins can be achieved by mutating the regulatory tyrosine residues to either 
phenylalanine or glutamic acid residues. This suggests that, similarly to the key Tyr174 residue 
(27, 31, 46), the hydroxyl groups of the sites that we identified probably contribute to stabilize 
the intramolecular inhibitory mechanism reported here. Crystallographic studies will be required 
to fully elucidate the multiple interdomain contacts that contribute to the inhibition of the 
catalytic activities of these proteins. 
 
SH3-mediated autoinhibition events have been described for other Rho GEFs, including 
intersectin (47, 48), kalirin (49), Rho GEF4 (also known as ArhGEF4 and adenomatous 
polyposis coli protein-stimulated GEF [Asef]) (50, 51), and Rho GEF5 (also known as ArhGEF5 
and transforming immortalized mammary oncogene product [TIM]) family members (52). The 
mechanism described here bears some similarity, but not identity, to the SH3-mediated 
autoinhibition of ArhGEF4 and ArhGEF5 family proteins. Thus, the autoinhibition of ArhGEF4 
is mediated by noncanonical interactions of its N-terminal SH3 domain with residues located in 
the DH-PH region, including the DH α6 helix (50, 51). However, in this case, the SH3 domain is 
directly involved in blocking the GTPase-binding site rather than in stabilizing a second 
inhibitory motif (50, 51). The activation step is also different, because it relies exclusively on the 
release of the SH3 domain through the interaction of other proteins with an adjacent motif (50). 
ArhGEF5 family proteins do have a double inhibitory system consisting of a tyrosine-based 
inhibitory motif and a CSH3 region (52); however, CSH3-mediated inhibition is based on the 
recognition of a PRR located outside of the DH-PH cassette (52). The mechanism by which this 
interaction is broken during signal transduction is not yet known. These results indicate that the 
SH3-regulated Rho GEF subfamilies use rather idiosyncratic mechanisms to transit in and out of 
the autoinhibited state. 
 
The autoinhibitory and phosphorylation-dependent activation mechanisms described here may 
provide additional regulatory layers for the spatiotemporal control of Vav proteins during cell 
signaling. For example, the requirement of multiple phosphorylation sites for the activation step 
offers an obvious buffering mechanism against spurious activation events derived from the 
stochastic phosphorylation of Vav proteins at single sites. Such background phosphorylation 
“noise” does exist in cells, as evidenced by the basal amount of Vav phosphorylation that we 
detected under unstimulated conditions. The intensity, diversity, or both of signaling downstream 
of Vav may also vary depending on the total number and location of the phosphotyrosines 
engaged at a given time (fig. S10, points vi and vii), thus offering a fine-tuning mechanism to 
adapt such signaling responses to the strength, duration, or type of incoming extracellular 
stimuli. In the same regulatory context, our observations indicating that mutation of the 
canonical PRR-binding site of the CSH3 domain enhances the interaction between CSH3 and 
Vav1 suggest that the association of PRR-containing proteins with phosphorylated Vav proteins 
may constrain the return to the autoinhibited state and, as a consequence, prolong Vav signaling 
under specific stimulation conditions or in specific subcelullar localizations (fig. S10, point vi). 
This may explain the reason for the high functional and structural diversity found so far for the 
canonical binding partners of Vav family CSH3 domains (4, 5). 
 
The dependency of an SH3-mediated interaction to maintain an autoinhibited state also has its 
disadvantages, because it could lead to spurious activation events through SH3-displacement 
mechanisms (fig. S10, point viii). In this context, it is worth noting that the CSH3 domain of Vav 
is a common signaling target for Nef and M2, two PRR-containing proteins encoded by HIV and 
γ-herpesviruses, respectively (53, 54). Such a mechanism may be at work in the case of Nef, 
because previous results have shown that it stimulates Vav proteins in a phosphorylation-
independent manner (53). It is also worth noting that our data do not exclude the possibility that, 
in addition to its direct effect on catalytic activity, the intramolecular localization of the CSH3 
domain might regulate the biological activity of Vav family proteins through additional 
mechanisms. For example, it is feasible that the release of the CSH3 domain during the 
activation step could favor the surface exposure of other regions of the molecule involved in 
interactions with other protein partners or cellular structures, such as the plasma membrane. 
Further work will be needed to fully understand all of the implications of this previously 
uncharacterized regulatory mechanism in the dynamic control of Vav proteins during both 
physiological and pathological signaling conditions. 
 
MATERIALS AND METHODS 
Antibodies 
Primary antibodies used in this study include a rabbit polyclonal antibody against Vav1 (#301-5) 
that was generated in house with a maltose-binding protein fused to the Vav1 DH domain 
purified from Escherichia coli as an immunogen (28); a rabbit polyclonal antibody against GST 
(Sigma); and monoclonal antibodies against human CD3 (UCHT1 clone, Merck Millipore), 
EGFP (Covance), tubulin α (Santa Cruz Biotechnology), chicken IgM (Southern Biotech), and 
hnRNPK (Merck Millipore). The rabbit polyclonal antibody that is specific for the 
phosphorylated Tyr174 residue of Vav1 has been described previously (27). The other phospho-
specific antibodies against Vav1 residues that were used here were generated with tyrosine-
phosphorylated peptides as immunogens (Invitrogen custom service). After their generation, the 
antibodies were positively and negatively selected by chromatographic steps with the appropriate 
phosphorylated and non-phosphorylated synthetic peptides. Specific recognition of the target 
phosphorylated sequence was demonstrated by ELISA with the appropriate phosphorylated and 
non-phosphorylated peptides and, in addition, by comparing the signals generated in Western 
blots with immunoprecipitated wild-type (WT) and phospho-site mutant versions of Vav1 from 
non-stimulated and EGF-stimulated COS1 cells (fig. S9). 
 
Cell lines 
Jurkat, DT40, COS1, and NIH3T3 cells were obtained, cultured, and stimulated as described 
previously (28, 55, 56). 
 
Expression vectors and in vitro mutagenesis 
All constructs used in this work used the mouse versions of mammalian Vav family members. 
Mammalian expression vectors encoding Vav1WT (pJC11), EGFP-Vav1Δ1-186 (pNM108), 
Vav1Y174F (pNM26), Vav1Δ1-186 (pKES12), Vav1Y3xF (pKES26), EGFP-Vav1Y3xF (pNM118), 
Vav1P833L (pKES42), EGFP-Vav1 DH-PH-ZF (pNM103), EGFP-Vav1 DH-NPH (pNM109), 
EGFP-Vav1 PH (pNM111), and EGFP-Vav1 ZF (pNM113) proteins were described previously 
(27, 28, 57). The Vav1Δ835-845-encoding mammalian expression vector pKES29 was generated by 
polymerase chain reaction (PCR) amplification with the Vav1WT-encoding vector pJC11 (57) as a 
template and the primers 5’-GCTCTGTCATGGACACCC-3' (forward, which amplifies just 
before the Bsu 36I restriction site present in Vav1 cDNA) and 5'-
AGCTAGTCTAGAATATTCAGTTAGAAGGGAACCAGCC-3' (reverse, with the Xba I 
cloning site underlined). The amplified cDNA fragment was digested with Bsu 36I and Xba I 
and then ligated into Bsu 36I- and XbaI-linearized pcDNA3 plasmid pKES18, which encodes 
Vav1WT. Plasmids encoding the EGFP-tagged Vav1Δ835-845 (pMB6) and Vav1Y3xF+Δ835-845 (pMB46) 
proteins were generated by PCR amplification with the EGFP-tagged Vav1WT–encoding vector 
pSRM3 as a template (58) and the primers: 5’-CCAGGACAAGAAAAGGAATG-3’ (forward, 
which amplifies from just before the Bam HI site present in Vav1 cDNA) and 5’-
AGCTAGGATCCAATATTCAGTTAGAAGGGAACCAGCC-3’ (reverse, with the Bam HI site 
underlined). The amplified cDNA fragment was digested with Bam HI and ligated into Bam HI–
linearized vectors encoding either EGFP-Vav1WT (pSRM3) or Vav1Y3xF (pKES14) (27). A 
mammalian expression vector encoding EGFP-tagged Vav2Δ860-868 (pMB127) was generated by 
introducing a stop codon in the Vav2 cDNA present in the EGFP-Vav2WT–encoding vector pAA7 
with the primers 5’-CGGTTGGTTTCCTTCGACGTAGGTGGAAGAGGAAGGCGTCCAG-3’ 
and 5’-CTGGACGCCTTCCTCTTCCACCTACGTCGAAGGAAACCAACCG-3’ (with the 
stop codon underlined). To generate the vector encoding EGFP-Vav3Δ841-847 (pMB121), a cDNA 
fragment was amplified by PCR with the pC-HA-Vav3 plasmid (Addgene) as template and the 
primers 5’-ATACTCGAGGCCACCATGGAGCCGTGGAAGCAGTGCGCTC-3’ (forward, 
with the Xho I site underlined) and 5’-
CCGGGCGAATTCTTATGTGGATGGAAACCAGCCCACCC-3’ (reverse, with the Eco RI 
site underlined). Upon digestion with Xho I and Eco RI, the Vav3Δ841-847 cDNA was ligated into 
the Bam HI– and Eco RI–linearized plasmid pEGFP-C2 (Clontech). To obtain vectors encoding 
DmVavWT (pMB122) and DmVavΔ781-793 (pMB128), the appropriate cDNA fragment was PCR 
amplified from the DmVav-encoding vector pID18 (37) with the primers 5’-
ATACTCGAGGCCACCATGGCCAGCAGCAGTAGCAGCAAC-3’ (forward, with the Eco RI 
site underlined) in both cases, and either the primer 5’-
CCGGGCGAATTCTCAAAGCTCTTCGCTGGCCAATTTCTG-3’ (reverse, with the Eco RI 
site underlined) or the primer 5’-
CCGGGCGAATTCTCACTTGGGAAAGTAGCCCACCGTATC-3’ (reverse, with the Eco RI 
site underlined) respectively, and cloned into pEGFP-C2, as described earlier. The expression 
vector encoding EGFP-Vav1 DH (pMB49) was generated by introducing a stop codon into the 
Vav1 cDNA present in pNM109, the vector encoding EGFP-Vav1 DH-NPH, with the primers 
5’-CTAGTGAAACACACACAGTAGGCTACAGAGAAGGAGAAC-3’ and 5’-
GTTCTCCTTCTCTGTAGCCTACTGTGTGTGTTTCACTAG-3’ (with the stop codon 
underlined). The expression vector pMB48, which encodes EGFP-Vav1 DH α6 helix, was 
generated by PCR amplification with pSRM3 as the template and the primers 5’-
GGCGAATTCCAGGAGCTAGTGAAACACACACAGGATGC-3’ (forward, with the Eco RI 
site underlined) and 5’-AGCTAGGATCCAATATTCAGTTCAGAGACTGGTCCAGGTTC-3’ 
(reverse, with the Bam HI site underlined). Upon digestion with Eco RI and Bam HI, the Vav1 
cDNA fragment was ligated into Eco RI– and Bam HI–linearized vector pEGFP-C2. Vectors 
encoding additional Vav1 mutant proteins (table S2) were generated by in situ mutagenesis 
techniques with the QuikChange mutagenesis kit (Agilent Technologies). Oligonucleotides used 
for the mutagenesis steps are shown in table S3. Baculovirus expression plasmids encoding 
6xHis-Vav1WT, 6xHis-Vav3WT, 6xHis-Vav1Δ1-144, 6xHis-Vav3Δ1-144, and 6xHis-Vav3 DH-PH were 
described previously (7, 28, 59). To express 6xHis-Vav1Δ835-845 and 6xHis-Vav3Δ841-847 in Sf9 cells, 
we mutated the pFastBac plasmids (Life Technologies) containing the full-length Vav1 and Vav3 
cDNAs to create a stop codon at the indicated truncation points to generate the pPTK3 and 
pMB149 vectors, respectively. The bacterial expression vector encoding GST-Vav1 CH 
(pJZL81) has been described previously (28). Vectors encoding GST-Rac1G15A [pGEX-
Rac1(15A)] and GST-RhoAG17A [pGEX-RhoA(17A)] were obtained from A. D. Cox (Chapel 
Hill School of Medicine, University of North Carolina, Chapel Hill, NC). The bacterial 
expression vector encoding the Vav1 CSH3 (pGEX-SH3) was obtained from P. Simas (Instituto 
de Medicina Molecular, Facultade de Medicina, Lisboa University, Lisbon, Portugal). This 
plasmid was used to generate the indicated mutations with the QuikChange mutagenesis kit (see 
tables S2 and S3). To express MBP-Vav1 DH-PH-ZF in bacteria, the Vav1 cDNA encoding 
these regions as well as 10 flanking amino acid residues was subcloned into the pMAL-c plasmid 
(New England Biolabs) according to standard procedures to generate the final pXRB7 plasmid. 
All newly generated plasmids were subjected to DNA sequence analysis to rule out the 
possibility of unwanted mutations. 
 
Biological assays 
For JNK activation assays in lymphoid cells, exponentially growing Jurkat cells (2 x 107 cells) 
and DT40 cells (1 x 107 cells) were co-electroporated (at 250 V and 950 µF) with pFR-Luc (10 
µg; Agilent Technologies), pFA2-cJun (5 µg, Agilent Technologies), and 20 µg of the 
appropriate Vav1-encoding expression vector. When required, electroporations were 
supplemented with empty plasmids to maintain a constant total amount of transfected DNA 
among samples. After 36 hours, cells were either left unstimulated or were stimulated with 
antibodies against human CD3 (in the case of Jurkat cells) or chicken IgM (in the case of DT40 
cells) for 7 hours, lysed, and then luciferase activities were determined with the Dual Luciferase 
Assay System (Promega). In the case of COS1 cells, exponentially growing cells were 
transfected with liposomes (Lipofectamine 2000, Invitrogen) with 1, 0.5, and 2 µg of the pFR-
Luc, pFA2-cJun, and appropriate expression vectors, respectively. Luciferase activity was 
determined 36 hours after transfection, as described earlier. For NFAT activation assays, cells 
were co-electroporated with the pNFAT/luc reporter vector (10 µg; provided by G. R. Crabtree, 
Stanford University, CA), pRL-SV40 (Promega), which encodes the Renilla luciferase (5 ng), 
and 20 µg of the appropriate experimental or empty expression vectors. After 36 hours, 
luciferase activities in unstimulated and stimulated cells were determined as described earlier. 
The values of firefly luciferase activity obtained in the different samples were always normalized 
to take into account the activity of the Renilla luciferase obtained in each sample. Results 
presented in figures represent the fold-change in the NFAT or JNK1 activities of the indicated 
experimental samples relative to those of unstimulated cells transfected with the control vector 
(which was given an arbitrary value of 1). Values are presented as means and standard deviations 
(SDs) from the indicated number of independent transfections, each of which were performed in 
triplicate. To confirm that comparable amounts of proteins were used in all samples, aliquots of 
lysates from the each of the experiments described earlier were subjected to SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE) and Western blotting analysis with appropriate antibodies. A 
representative example of these Western blotting analyses is included in each figure. To analyze 
the F-actin cytoskeleton, 1 x 106 Jurkat cells were transfected with 30 µg of the indicated 
expression plasmids with the Neon Tranfector System (Program #5; Invitrogen). After 36 hours, 
cells were transferred onto 12-mm diameter, poly-D-lysine-coated coverslips (BioCoat) and 
allowed to settle for 20 min. In the case of COS1 cells, cells in each 6-well culture plate were 
transfected with 1 µg of the plasmid of interest with Lipofectamine 2000. After 24 hours, cells 
were trypsinized, plated onto 12-mm diameter coverslips (Menzel-Glaser) pre-treated for 10 min 
with poly-L-Lysine (1 µg/ml, Invitrogen), and then cultured for 12 to 24 hours. After these 
specific procedures, all cells were fixed in 4% formaldehyde in phosphate-buffered saline (PBS) 
for 15 min, washed twice with PBS, permeabilized in 25 mM Tris-HCl (pH 8.0) containing 0.5% 
Triton X-100 (Sigma) for 10 min, washed three times with TBS-T [25 mM Tris-HCl (pH 8.0), 
150 mM NaCl, 0.1% Tween-20], and blocked for 15 min with 2% bovine serum albumin (BSA, 
Sigma) in TBS-T. After a 20-min incubation with rhodamine-labeled phalloidin (Invitrogen; 
diluted 1:200 in TBS-T, 2% BSA) to visualize the F-actin cytoskeleton, cell preparations were 
washed thrice with TBS-T, and mounted onto microscope slides with Mowiol (Calbiochem). In 
the case of Jurkat cells, 4’,6-diamidino-2-phenylindole (Invitrogen, 1 µg/well) was included for 5 
min in the last washing step to label the cell nuclei. Samples were analyzed with a Leica TCS 
SP5 confocal microscope. Images were captured with LAS AF software (version 2.6.0.72266, 
Leica). Focus formation assays were performed with NIH3T3 cells as previously described (28, 
60). GTPase-linked immunosorbent assays were performed with a commercial kit 
(Cytoskeleton), as described previously (19, 23). 
 
Protein detection by Western blotting analysis 
Immunoprecipitations and Western blotting analysis were performed according to standard 
protocols, as described previously (55). 
 
GDP-GTP exchange assays 
Proteins were expressed and purified from baculovirus-infected Sf9 cells as described previously 
(7, 59), and then were gel-quantified with BSA (Sigma) as a concentration standard. The final 
concentration of 6xHis-tagged proteins (0.25, 0.5, 0.8 or 1 µM) used in the GDP-GTP exchange 
reactions is indicated in the appropriate figures. Where indicated, 6xHis-Vav1WT was 
phosphorylated in vitro with a GST-Lck fusion protein purified from Sf9 cells, as described 
previously (7, 59). As controls, we performed kinase reactions containing either Vav1WT or the 
kinase alone. After the kinase reactions were incubated at room temperature for 30 min, aliquots 
were taken and used in GDP-GTP exchange reactions. The final concentrations of Vav1 and Lck 
in these assays were 1 and 0.1  µM, respectively. Exchange assays were performed with a 
commercial kit (RhoGEF exchange assay BK100, Cytoskeleton). In some experiments, we used 
the human Dbs DH-PH region, which was provided by the exchange assay kit, as a comparative 
control at the recommended final concentration of 0.8 µM. The 6xHis-tagged GTPases provided 
by the kit were used in these reactions at a final concentration of 2 µM in all assays. 
Fluorescence activities were measured every 30 s for 30 min with a Synergy 4 plate reader 
(Biotek) with Gen5 software (Biotek). For graphical representation, raw data were imported into 
Excel 12.3.6 (Microsoft), selecting values obtained in 150-s intervals for final representation. 
 
Purification of proteins from E. coli 
Isopropyl β-D-1-thiogalactopyranoside–induced GST and MBP proteins in E. coli were purified 
with glutathione-Sepharose (GE Healthcare Life Biosciences) and amylose-coated beads (New 
England Biolabs), respectively. In the case of MBPs, cultures were induced for 1 hour at 25°C to 
minimize the generation of truncated versions that ran with a mobility of ~37 to 42 kD by SDS-
PAGE (containing mostly MBP alone). After washes, GST and MBP proteins were eluted with 
10 mM glutathione (Sigma) and 10 mM maltose (Sigma), respectively. Eluted proteins were 
dialyzed in PBS and used as indicated in the figure legends. In the case of pull-down 
experiments, GST proteins were kept immobilized on glutathione-Sepharose beads. For plasmon 
resonance determinations, the purified MBP-DH-PH-ZF protein was subjected to a size 
exclusion chromatography step with an fast protein liquid chromatography apparatus (GE 
Healthcare Life Biosciences) to eliminate the aforementioned small MBP fragments that co-
purified with the full-length MBP-DH-PH-ZF chimeric protein. In all cases, protein quantitation 
was performed with electrophoresed aliquots of samples and gradients of BSA as standards. 
 
GST pull-down experiments 
COS1 cells were transfected with 8 µg of each plasmid by the diethylaminoethyl-
dextran/chloroquine method (61) and were cultured for a further 48 hours. Cells were then 
washed with PBS and disrupted in lysis buffer [20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM 
MgCl2, 0.5% Triton X-100, 5 mM β-glycerophosphate (Sigma), 1 mM dithiothreitol (DTT, 
USB), and a mixture of protease inhibitors (Cømplete, Roche)]. After eliminating cellular debris 
by centrifugation at 18,600 xg for 10 min at 4°C, lysates were incubated for 5 hours at 4°C with 
~25 µg (in the case of Rac1G15A and RhoAG17A) or 15 µg (for the rest of the assays) of the 
indicated GST proteins purified from E. coli. Protein complexes were trapped with glutathione-
sepharose beads (GE Healthcare Life Biosciences), washed thrice in lysis buffer, resuspended in 
SDS-PAGE sample buffer, fractionated electrophoretically, and subjected to Western blotting 
analysis with antibodies against Vav1, EGFP, or hnRNPK. To detect the GST proteins brought 
down by the beads, blots were stained with a Ponceau solution (Sigma) before the Western 
blotting step. Alternatively, the samples were analyzed by Western blotting with antibodies 
against GST after the detection of the pulled down proteins. Aliquots of the same cell lysates that 
were used for the pull-down experiments were fractionated electrophoretically and subjected to 
Western blotting analysis to determine the amount of protein in each case. The minimal number 
of repetitions of an experiment is given in the appropriate figure legend. 
 
Surface plasmon resonance determinations 
These experiments were performed with a Biacore X-100 equipment (Biacore AB) at the Centro 
de Investigaciones Biológicas facility. GST-CSH3WT protein was immobilized onto a sensor chip 
CM5 (GE Healthcare) through the amine-coupling procedure according to the supplier’s 
instructions. Experiments were performed in HBS-EP running buffer [0.01 M HEPES (pH 7.4), 
150 mM NaCl, 3 mM EDTA, 0.005% (vol/vol) surfactant P20]. MBPs (100 µM) were dialyzed 
overnight in running buffer without surfactant and then were injected at a flow rate of 30 µl/min 
through both GST-CSH3WT-containing and non-protein–containing (control) cells. Dissociation 
was performed in HBS-EP running buffer. For graphical representation, raw data were imported 
into Prism-5 (GraphPad) and plotted. When required, regeneration of the cell chip was 
performed with an injection of 50 mM NaOH for 30 seconds. 
 
EM analysis and 3D reconstruction 
A 6xHis-tagged version of the Vav1Δ1-144 mutant protein was expressed in insect Sf9 cells and 
purified by metal affinity chromatography, as described previously (6, 7). Eluates were subjected 
to size-exclusion chromatography with a Superdex 200 PC3.2/30 column (GE Healthcare) 
equilibrated in 50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1mM MgCl2, 1 mM DTT, and 10% 
glycerol. Aliquots of fractions obtained were analyzed by SDS-PAGE and silver stained or, 
alternatively, were adsorbed on carbon-coated grids, stained with 2% (w/v) uranyl formate 
(Sigma), and analyzed in a JEOL 1230 transmission electron operated at 100 kV. EM images 
were collected with a low-dose protocol and a 4k x 4k TVIPS CMOS detector under the control 
of EM-TOOLS software (TVIPS). Final magnification of the CMOS micrographs was 68,222×, 
which were then down-sampled to a final 4.56 Å per pixel. The contrast transfer function for 
each micrograph was estimated with CTFFIND3 (contrast transfer function and FIND 3) (62) 
and corrected with Bsoft (Bernard’s software) (63). 4,970 images of individual molecules were 
selected from micrographs and processed with EMAN (64). Reference-free averages were 
obtained from XMIPP (X-Window-based microscopy image processing package). The structure 
was obtained by angular refinement methods as implemented in EMAN (electron microscopy 
analysis) (64) and with several templates for refinement, including different random noisy 
Gaussian blobs, which converged to the same solution. The resolution of the structures was 
estimated as 32.5 Å by Fourier shell correlation and a 0.5 correlation coefficient. 
 
Structural modeling 
Visualization of protein structures was performed with MacPyMol software (version 1.5, 
DeLano Scientific LLC). Protein data bank (PDB) files for Vav1 CH-Ac-DH-PH-ZF (3KY9), 
Vav1 DH-PH-ZF (2VRW), and Vav CSH3 (2DM1 and 2KBT) were retrieved from the RCSB 
PDB. The structure of the Vav1 CSH3 domain was modeled bioinformatically from the PDB 
2DM1 file with Phyre2 software (www.sbg.bio.ic.ac.uk/phyre2) (65). 
 
Phospho-site determinations 
Vav1 immunoprecipitates obtained from unstimulated and EGF-stimulated COS1 cells and from 
unstimulated and anti-CD3–stimulated Jurkat cells were separated electrophoretically and 
stained with imidazole and zinc. Bands corresponding to Vav1 were cut from the gel, 
trypsinized, and analyzed with a MALDI-TOFF apparatus (Ultraflex, Bruker). Phospho-sites 
detected in three independent determinations were used for further characterization. In addition 
to the sites described in this work, we also detected that Tyr725 of Vav1 was phosphorylated only 
in the case of EGF-stimulated COS1 cells. We have also identified a number of serine and 
threonine residues that were not characterized in this study. To confirm the phosphorylation of 
those sites using independent techniques, we analyzed their phosphorylation status in Vav1 
immunoprecipitates obtained from Jurkat cells that were subjected to Western blotting analyses 
with phospho-specific antibodies. After this step, blots were stripped and then incubated with 
antibodies specific for Vav1. 
 
Image-processing 
All images and figures were assembled and processed for final presentation with Canvas 12 
software (Deneba Systems). 
 
Statistical analyses 
Where indicated, the Mann-Whitney U test was applied to the data using, as a minimum, three 
independent experiments, each of which were performed with triplicate samples. *P ≤ 0.05, **P 
≤ 0.01, and ***P ≤ 0.001. In all figures, data values and error bars are given as means ± SEM. 
 
SUPPLEMENTARY MATERIALS 
Fig. S1.  The known activation step of Vav family proteins. 
Fig. S2. Truncation of the CSH3 domain promotes the activation of Vav1 in cells. 
Fig. S3.  The Vav1 CSH3 domain does not interact with the Vav1 PRR-NSH3 region. 
Fig. S4. The CSH3 inhibits Vav1 in cis. 
Fig. S5. EM structure of unphosphorylated 6×His-Vav1Δ1-144. 
Fig. S6. Characterization of residues of the DH domain α6 helix that contribute to the stability of 
the inhibitory CSH3-Vav1 interaction. 
Fig. S7. The CSH3 domain of Vav1 uses two different topological regions to interact with the 
DH and PH domains. 
Fig. S8. Effect of the mutation of CSH3 DFC-R and YVEED sites in Vav1 biological activity. 
Fig. S9. Characterization of phospho-specific antibodies specific for Vav1. 
Fig. S10. Proposed model for the regulation of Vav family proteins. 
Table S1. Detection of indicated phosphosites in Vav1 using mass spectrometry. 
Table S2. List of additional plasmids. 
Table S3.  List of primers. 
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Fig. 1. Characterization of the inhibitory action of the CSH3 domain of Vav1. (A) Outlines 
of the wild-type (WT) and mutant Vav1 proteins used in this work. (B) The Vav1 signaling 
pathway in T cells. The direct Rac1-dependent pathway stimulated by Vav1 is shown in red. 
Responses requiring additional signaling elements are in black. cNFAT, cytosolic NFAT; 
nNFAT, nuclear NFAT. (C to F) Analysis of the extent of JNK activation by the indicated Vav1 
proteins expressed in (C and E) WT and (C) TCR-deficient Jurkat cells that were either left 
unstimulated or were stimulated with anti-CD3 antibody (α-CD3). (D and F) The abundances of 
the ectopically expressed proteins and tubulin α (as a loading control) were determined by 
Western blotting (WB) analysis. Representative experiments are shown. (G) Confocal 
microscopy was used to analyze the cytoskeletal changes induced by the indicated Vav1 proteins 
in unstimulated Jurkat cells. Scale bar: 5 µm. Images are representative of four experiments. (H) 
Analysis of the activation of NFAT by the indicated Vav1 proteins in unstimulated (-) and 
stimulated (+) Jurkat cells (left) and DT40 cells (right). (I) The abundances of the ectopic 
proteins and of the loading control in a representative experiment from (H) were determined by 
Western blotting analysis. In (C), (E), and (H), P values are given relative to unstimulated cells 
(red asterisks) and stimulated cells (blue asterisks) cells expressing Vav1WT or, alternatively, for 
the indicated experimental pairs (brackets). *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001. Data are 
means ± SEM from six experiments for Jurkat cells and three experiments for DT40 cells. Each 
experiment was performed with triplicate samples. NS, not significant. 
 
Fig. 2. CSH3-mediated inhibition is a common regulatory feature of Vav family members. 
(A and B) Analysis of the activation of JNK in COS1 cells transfected with plasmids expressing 
EGFP alone or EGFP fusions of the indicated Vav1 proteins. P values are given relative to either 
Vav1WT or the indicated experimental pairs (in brackets). Data are means ± SEM from three 
independent experiments, each performed with triplicate samples. ***P ≤ 0.001. (B) The relative 
abundances of the expressed proteins and loading controls were determined by Western blotting 
analysis and are shown from one representative experiment. DmVav, Drosophila melanogaster 
Vav. (C) Example of oncogenic activity exhibited by the indicated Vav1 proteins in NIH3T3 
focus formation assays. Similar results were obtained in two additional experiments, each of 
which was performed in triplicate. (D) Analysis of JNK activity in Jurkat cells transfected with 
plasmid encoding EGFP alone or the indicated EGFP-tagged Vav proteins and then left 
unstimulated or stimulated with anti-CD3 antibody. (E) Western blotting analysis of the cells 
used in (D) was performed with antibodies against the indicated proteins. One representative 
experiment is shown. P values in (D) are given as for Fig. 1C. Data are means ± SEM from three 
independent experiments, each performed in triplicate. 
 
Fig. 3. The CSH3 domain inhibits the enzymatic activity of Vav. (A) Gel showing the 
aliquots of 6×His-Vav proteins used in this study. MWM, molecular weight marker. (B to D) 
Analysis of the GDP-GTP exchange activity of the indicated amounts of Vav1 and Dbs proteins 
on the (B) Rac1, (C) RhoA, and (D) Cdc42 GTPases over time. Data are from three independent 
experiments. a.u., arbitrary units. (E) Western blotting analysis of the phosphorylation of 6×His-
Vav1WT in the presence or absence of GST-Lck. (F) Aliquots of in vitro kinase reactions 
containing 6xHis-Vav1WT alone, GST-Lck alone or 6xHis-Vav1WT plus GST-Lck were tested in 
Rac1 GDP/GTP exchange assays. The final concentration of each protein in the exchange 
reaction is indicated on the right. Data are from two independent experiments. Note that only 
aliquots from kinase reactions containing Vav1 and Lck proteins showed activity in this assay. 
(G to I) Exchange activity of the indicated concentrations of the indicated Vav3 and Dbs 
proteins on (G) Rac1, (H) RhoA, and (I) Cdc42. Data are from three independent experiments. 
(J) Top: Western blotting analysis of pull-down reactions containing the indicated Vav proteins 
and GST-tagged GTPases. Middle: Analysis of the amounts of GST proteins. Bottom: Western 
blotting analysis of the amounts of input Vav proteins. (K) Analysis of endogenous Rac1 activity 
in COS1 cells expressing the indicated Vav proteins. P values are given relative to data obtained 
with Vav1WT or the indicated experimental pairs (brackets). Data are means ± SEM from three 
independent experiments, each performed in triplicate. (L) Western blotting analysis of the 
abundances of Vav proteins and tubulin α (loading control) in the samples used in (K). Blots are 
from a single representative experiment. 
 
Fig. 4. The CSH3 inhibits Vav1 in cis. (A) Analysis of the activity of JNK (top) and NFAT 
(bottom) in Jurkat cells that were left untransfected (None) or were transfected with plasmids 
encoding the indicated Vav1 proteins and then were left untreated or were treated with anti-CD3 
antibody. P values are given as described for Fig. 1C. Data are from three independent 
experiments, each performed in triplicate. (B) Western blotting analysis of ectopic protein 
abundance and loading controls for the experiments shown in (A). Data are from a single 
representative experiment. (C) Scheme showing the rationale used in our pull-down experiments. 
SBS, SH3-binding site. (D to H) Analysis of the interactions between GST-tagged proteins and 
Vav1 proteins. (D, E, G, and H) Top: Data show pull-down assays between the indicated GST-
tagged proteins and the indicated Vav1 proteins. In (D), the EGFP tag was only used in the case 
of Vav1Δ1-186. The relative amounts of bait and ectopically expressed proteins used in the pull-
down assays are shown in the middle and lower panels, respectively. Data are representative of a 
single experiment, and similar results were obtained in three additional experiments. (F) The 
EGFP-Vav1 proteins used in the pull-down assays. The shaded area indicates domains that show 
positive interactions with the GST-CSH3 bait protein (see G and H). Note that the NPH fragment 
cannot form a functional PH domain because it lacks critical residues for proper domain folding. 
(I) Analysis of purified GST and MBP proteins. β-gal, β-galactosidase. (J) Surface plasmon 
resonance measurements were used to determine interactions between the indicated purified 
MBPs and GST-CSH3WT shown in (I). Two independent injections are shown. 
 
Fig. 5. The DH domain α6 helix stabilizes the CSH3-Vav1 interaction. (A) Top: The 
sequence of the Vav1 DH domain α6 helix indicating areas contained in EGFP-DH-NPH (white 
box) and EGFP-PH (gray box) that showed positive interactions with GST-CSH3P833L (Fig. 4). 
Mutated residues are colored. Bottom: The 3D structure of the Vav1 DH domain α6 helix 
showing the positions of the mutated residues. (B) Top: Analysis of the interaction between 
GST-CSH3P833L and the indicated untagged Vav1 proteins expressed in COS1 cells. The relative 
amounts of GST-CSH3 bait protein (middle) and ectopically expressed Vav1 proteins (bottom) 
were determined by Ponceau staining and Western blotting analysis, respectively. Data are 
representative of three independent experiments. (C) Jurkat cells were transfected with plasmids 
encoding the indicated proteins and then were left untreated or were treated with anti-CD3 
antibody before being analyzed for JNK (top) and NFAT (bottom) activities. P values are given 
as for Fig. 1C. Data are from three independent experiments, each performed in triplicate. (D) 
Protein abundances and loading controls for the samples analyzed in (C) were determined by 
Western blotting analysis. Data are from a single representative experiment. (E) Top: 
Interactions between the indicated Vav1 proteins and GST-Rac1G15A. The relative amounts of 
GST proteins (middle) and the input amounts of Vav1 proteins (bottom) used in the pull-down 
assays were determined. Data are representative of four independent experiments. 
 
Fig. 6. The CSH3 domain of Vav1 uses two binding sites to interact with the DH and PH 
domains. (A) Primary (top) and 3D (bottom) structures of the Vav1 CSH3 domain indicating 
residues mutated in these experiments (in light and dark red). The PRR-binding site is in green. 
(B) Top: Pull-down assays showing interactions between the GST-CSH3P833L fusion protein and 
the indicated Vav1 proteins. The amounts of bait protein (middle) and ectopically expressed 
proteins (bottom) proteins is shown. Data are representative of three independent experiments. 
(C to G) Jurkat cells were transfected with plasmids encoding the indicated proteins and then 
were left untreated or were treated with antibody against CD3. Samples were then analyzed to 
determine the extent of (C and F) JNK activation and (E) F-actin polymerization. (D and G) The 
abundances of Vav1 proteins (upper panels) and loading controls (lower panels) were determined 
by Western blotting. Data from representative experiments are shown. P values in (C) and (E) 
are given as for Fig. 1C. Data are from three independent experiments. (H) Analysis of 
interactions between the indicated GST-CSH3 proteins (indicated underneath the middle panel) 
and Vav1 domains (top). The amounts of bait protein (middle) and ectopic proteins (bottom) are 
shown. Data are representative of four independent experiments. The specific interaction sites of 
the DH and PH domains with the CSH3 identified in these experiments are also depicted in panel 
A (bottom, structure on the right). 
 
Fig. 7. Vav1 is regulated by multiple phosphorylation sites. (A) Jurkat cells were left 
unstimulated or were stimulated with anti-CD3 antibody for the indicated times before being 
subjected to immunoprecipitation (IP) with anti-Vav1 antibody. The kinetics of the 
phosphorylation of the indicated tyrosine residues in Vav1 were determined by Western blotting 
analysis with phospho-specific antibodies. As controls, the indicated blots (matched by the same 
colored asterisks) were stripped and reanalyzed with anti-Vav1 antibodies. Data are 
representative of eight independent experiments. (B) Analysis of the JNK activity of Jurkat cells 
transfected with plasmids expressing the indicated proteins and then left untreated or treated with 
anti-CD3 antibody. P values are given as for Fig. 1C. Data are means from three independent 
experiments, each performed in triplicate. (C) The abundances of the expressed Vav1 proteins 
(top) and loading controls (bottom) of the samples used in (B) were determined by Western 
blotting analysis. Data from a single representative experiment are shown. (D and E) Pull-down 
assays were performed to determine interactions between the indicated Vav1 proteins and (D) 
GST-CSH3P833L and (E) GST-Rac1G15A. Data in (D) and (E) are representative of two and three 
independent experiments, respecitvely. The amounts of bait (middle) and ectopically expressed 
(bottom) proteins were determined. (F) Depiction of the intramolecular mechanism involved in 
the phosphorylation-dependent activation of Vav family proteins. Light blue rectangle: the α 
helix that harbors the Ac domain Tyr174 phospho-site; dark blue and red rectangles: non-
canonical interaction motifs of the CSH3 domain; light blue dots: non-phosphorylated tyrosine 
residues; yellow dots phosphorylated tyrosine residues (pY); red asterisks: mutations in 
phosphor-sites in the Ac region. The depicted movements of the CH-Ac and NSH3-SH2-CSH3 
regions are hypothetical. 
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Fig. S1. The known activation steps of Vav family proteins. (A) Schematic 
representation of the physiological (green arrows) and oncogenic (red arrows) mechanisms 
of activation of Vav family proteins. The localization of the CH-Ac region depicted in the 
open conformation is hypothetical, because no 3D structures are available. The specific 
localization of the NSH3-SH2-CSH3 cassette in both the inactive and active conformations 
of these proteins is also unknown for the same reason. The α helix that harbors the Ac 
domain Tyr174 phospho-site is depicted as a blue rectangle. Light blue dots represent non-
phosphorylated tyrosine residues, whereas yellow dots represent phosphorylated tyrosine 
(pY) residues. Red asterisks indicate mutations in phospho-sites. Further details are given 
in the main text. (B) Crystal structure of the CH-Ac-DH-PH-ZF region of Vav1 (31). 
Broken lines indicate regions that could not be solved in the crystal structure. 
 
 
Fig. S2. Truncation of the CSH3 domain promotes the activation of Vav1 in cells. (A) 
COS1 cells transfected with plasmids expressing EGFP or the indicated EGFP-tagged Vav1 
proteins were fixed, treated with rhodamine-labeled phalloidin to stain the F-actin 
cytoskeleton, and then analyzed by confocal microscopy. Ectopic proteins were detected 
through the epifluorescence of the EGFP tag. Scale bar: 5 µm. Images are representative of 
four independent experiments. (B) Jurkat cells (top) and DT40 cells (bottom) were 
transfected with plasmids encoding the indicated proteins and then were left unstimulated 
or were stimulated through their respective antigen receptors before NFAT activity was 
determined. P values are given relative to both nonstimulated (red asterisks) and stimulated 
(blue asterisks) cells expressing Vav1WT. Data are means ± SEM from three independent 
experiments. (C) The abundance of indicated proteins from the cells used in (B) were 
determined by Western blotting analysis. Data from a representative experiment are shown. 
 
 
Fig. S3. The Vav1 CSH3 domain does not interact with the Vav1 PRR-NSH3 region. 
(A) Schematic representation of wild-type (WT) Vav1 and some of the Vav1 mutant 
proteins used in this experiment. (B) Scheme showing the rationale for the strategy used in 
these pull-down experiments. Mutations are depicted as red asterisks. (C) Top: Pull-down 
assays were performed to determine interactions between the GST-CSH3P833L fusion protein 
and the indicated full-length (lanes 1 to 5) and Vav1Δ835-845 mutant proteins (lanes 5 to 8). 
Middle: The relative amounts of bait proteins were determined by Ponceau staining of the 
same blot. Bottom: The presence of the indicated Vav1 proteins was confirmed by Western 
blotting analysis of aliquots of the same total cellular lysates used in the pull-down assays 
with the indicated antibody. Data are representative of two independent experiments. 
 
 
 
 
 
 
 
 
 
Fig. S4. The CSH3 domain inhibits Vav1 in cis. (A) Top: Pull-down assays were 
performed to investigate interactions between the indicated GST bait proteins and EGFP-
tagged Vav1 proteins. The relative amounts of bait proteins and ectopically expressed 
proteins used in each pull-down assay were determined by Ponceau staining (middle) and 
Western blotting analysis (bottom), respectively. Data are representative of four 
independent experiments. (B) Pull-down assays were performed to investigate interactions 
between the indicated GST fusion proteins and the EGFP-Vav1 DH-PH-ZF region. The 
relative amounts of bait and ectopically expressed proteins used in each pull-down assay 
were determined by Ponceau staining (middle) and Western blotting analysis (bottom), 
respectively. Data are representative of three independent experiments. 
 
 
 
 
 
 
 
 
 
Fig. S5. EM structure of unphosphorylated 6×His-Vav1Δ1-144. (A) Elution profile of 
6×His-Vav1Δ1-144 purified by size exclusion chromatography. The indicated fractions were 
analyzed by SDS-PAGE (inset), and the peak (boxed) was selected for EM analysis. (B) 
Representative images from the 2D EM analysis of purified 6×His-Vav1Δ1-144 protein. The 
“head” and “tail” regions are indicated. (C) Several reference-free averages obtained for 
6×His-Vav1Δ1-144 after classification of single molecule images. (D) Two orthogonal views 
of the 3D structure of 6×His-Vav1Δ1-144 (white translucent density) obtained by EM analysis 
and image-processing methodologies. The putative localization of the indicated domains of 
Vav1 and Grb2 is shown. The position of the SH3 domain of Grb2 that had to be displaced 
to fit within the density of the molecule is indicated as a green sphere that has the 
approximate size of the domain. The original position of the SH3 domain is shown in red. 
The rotation required for fitting that domain within the volume of 6×His-Vav1Δ1-144 is 
indicated by an arrow. 
 
 
 
 
 
Fig. S6. Characterization of residues of the DH domain α6 helix that contribute to the 
stability of the inhibitory CSH3-Vav1 interaction. (A and B) Stereospatial views of the 
Vav1 DH domain α6 helix in the context of the crystal structures of (A) the CH-Ac-DH-
PH-ZF region and (B) the DH-PH-ZF region of Vav1. Mutated residues are depicted as 
sticks. Those amino acid residues with roles in the stability of the intramolecular CSH3-
Vav1 interaction are boxed. (B) The connectivity of these residues with amino acids present 
in other Vav1 domains or the Rac1 switch II region is indicated as broken lines. The 
specific amino acid residues that establish bonds with those mutated residues are also 
indicated. Structural data were based on previous publications (29-31). 
 
 
 
 
 
 
 
 
Fig. S7. The CSH3 domain of Vav1 uses two different topological regions to interact 
with the DH and PH domains. (A) Primary sequence (top) and two different views of the 
3D structure of the Vav1 CSH3 domain (bottom) with the residues mutated in these 
experiments highlighted in color. (B) Pull-down assays were performed to investigate the 
interaction of the GST-CSH3P833L fusion protein with the indicated Vav1 proteins. The color 
code for the indicated amino acid residues is the same as that for (A). The relative amounts 
of bait protein (middle) and ectopically expressed Vav1 proteins (bottom) were determined 
by Ponceau staining and Western blotting analysis, respectively. Data are representative of 
four independent experiments. 
 
 
Fig. S8. Effect of the mutation of CSH3 DFC-R and YVEED sites in Vav1 biological 
activity. (A and B) Jurkat cells were transfected with plasmids expressing indicated 
proteins and, upon left untreated (–) or being stimulated (+) with an anti-CD3 antibody, 
assayed for NFAT activity (A). P values are given as for Fig. 1C (n = 3). The amount of 
ectopic proteins obtained in each experiment was determined by Western blotting analysis 
with antibodies to the EGFP tag. As loading control, we measured the abundance of tubulin 
α in each sample. Western blot data from a single representative experiment are shown (B). 
(C and D) Analysis of JNK activity in COS1 cells transfected with plasmids expressing 
EGFP alone or indicated EGFP-Vav1 chimeras (C). P values are given relative to activity 
shown by Vav1WT (n = 3).  Controls for protein expression (D) were done as for 
experiments shown in panels (A) and (B). (E) Top: Pull-down assays were performed to 
investigate interactions between indicated Vav1 and GST-GTPase proteins. The amounts of 
bait and ectopically expressed proteins used in each pull-down assay were determined by 
Ponceau staining (middle) and Western blotting analysis (bottom), respectively. (F) Top: 
Pull-down assays were performed to determine interactions between endogenous hnRNPK 
and GST-CSH3 proteins harboring the indicated mutations in the Vav1 CSH3 domain. The 
amounts of bait and endogenous hnRNPK used in each pull-down assay were determined 
as in (E). Data in (E) and (F) are representative of two independent experiments. 
 
 
 
 
 
 
 
 
Fig. S9. Characterization of phospho-specific antibodies specific for Vav1. (A to F) 
COS1 cells were transiently transfected with plasmids encoding WT Vav1 or the indicated 
Vav1 mutant proteins and then serum-starved and stimulated with EGF for 10 min as 
indicated. Upon cell lysis and immunoprecipitation using the same anti-Vav1 antibody, the 
phosphorylation of the WT and indicated mutant versions of Vav1 was determined by 
Western blot using antibodies specific to the phosphorylated Tyr142 (A, top panel), Tyr160 
(B, top panel), Tyr174 (C, top panel), Tyr541 (D, top panel), Tyr544 (E, top panel), and Tyr836 
(F, top panel) residues.  The blots were then stripped and re-analyzed with a rabbit 
polyclonal antibody specific for total Vav1 (A to F, bottom panels). Data are representative 
of three independent experiments. 
  
 
Fig. S10. Proposed model for the regulation of Vav family proteins. Physiological 
(green arrows) and spurious (red arrows) mechanisms of activation are shown. Icons used 
are the same as those used in fig. S1A. The depicted movements of the CH-Ac and NSH3-
SH2-CSH3 regions during the activation steps are hypothetical. There can be other “gray 
zone states” than those depicted (vii-1 to vii-3) if we take into account the possible 
permutations of phosphorylated residues, interacting proteins, or both. For the sake of 
simplicity, we have not included the interaction of Vav proteins with other signaling 
molecules. The old regulatory model can be found in fig. S1A. 
  
 
 
 
Table S1. Detection of indicated phosphosites in Vav1 using mass spectrometry. 
 
Tryptic peptide detected by mass spectometrya 
 
Phosphorylated 
tyrosine 
residue(s)b 
Conditionc 
VIYTLSALSWTPIAQNK 110 NS, SC, SJ 
CQMLLRGTFYQGYRCYR 541, 544 SC, SJ 
AFRGLLELVEFYQQNSLKDCFK 745 SC 
IGWFPSNYVEEDYSEYC 836 SC, SJ 
   
LESVPTPPKMTEYDKR 192d SC, SJ 
DALAGPGATTLYQVFIK, 
DALAGPGATTLYQVFIKYKR 
267d SC, SJ 
YAFLLDKALLICKR 423d SC 
CQMLLRGTFYQGYRCYR 541, 544, 547d SC 
aPhosphorylated tyrosine residue is indicated in red bold font. 
bPhosphorylated residues identified using a LCQ DECA XP apparatus (Thermo Finnigan). 
cNS, phosphosite detected in non-stimulated COS1 and Jurkat cells; SC, phosphosite 
detected in EGF-stimulated COS1 cells; SJ, phosphosite detected in TCR-stimulated Jurkat 
cells. 
dPhosphosite not consistently identified in all experiments. 
  
Table S2. List of additional plasmids. 
 
Name 
 
Vector backbone Encoded protein 
pKES27 pMEX Vav1Y3xF+Δ835-845 
pMB35 pGEX 6P-1 GST-CSH3P833L 
pMB52 pEGFP-C2 EGFP-Vav1AAAP 
pMB50 pEGFP-C2 EGFP-Vav1P651L 
pMB53 pEGFP-C2 EGFP-Vav1AAAP+P651L 
pMB54 pEGFP-C2 EGFP-Vav1AAAP+Δ835-845 
pMB51 pEGFP-C2 EGFP-Vav1P651L+Δ835-845 
pMB55 pEGFP-C2 EGFP-Vav1AAAP+P651L+Δ835-845 
pMB69 pEGFP-C2 EGFP-Vav1NEmut+Δ835-845 
pMB70 pEGFP-C2 EGFP-Vav1VKmut+Δ835-845 
pMB71 pEGFP-C2 EGFP-Vav1RDmut+Δ835-845 
pMB72 pEGFP-C2 EGFP-Vav1NE+RDmut+Δ835-845 
pMB73 pEGFP-C2 EGFP-Vav1NEVKRDmut+Δ835-845 
pMB74 pEGFP-C2 EGFP-Vav1T384A+Δ835-845 
pMB75 pEGFP-C2 EGFP-Vav1L388A+Δ835-845 
pMB90 pEGFP-C2 EGFP-Vav1V373A+Δ835-845 
PMB91 pEGFP-C2 EGFP-Vav1K374A+Δ835-845 
pMB92 pEGFP-C2 EGFP-Vav1R375A+Δ835-845 
pMB93 pEGFP-C2 EGFP-Vav1D376A+Δ835-845 
pMB98 pEGFP-C2 EGFP-Vav1R375A 
pMB99 pEGFP-C2 EGFP-Vav1D376A 
pMB77 pEGFP-C2 EGFP-Vav1D792A 
pMB86 pEGFP-C2 EGFP-Vav1F793A 
pMB87 pEGFP-C2 EGFP-Vav1C794A 
pMB78 pEGFP-C2 EGFP-Vav1R796A 
pMB88 pEGFP-C2 EGFP-Vav1K804A 
pMB89 pEGFP-C2 EGFP-Vav1N835A 
pMB58 pEGFP-C2 EGFP-Vav1R790A 
pMB59 pEGFP-C2 EGFP-Vav1Y791A 
pMB60 pEGFP-C2 EGFP-Vav1D797A 
pMB61 pEGFP-C2 EGFP-Vav1R798A 
pMB62 pEGFP-C2 EGFP-Vav1S799A 
pMB63 pEGFP-C2 EGFP-Vav1E805A 
pMB64 pEGFP-C2 EGFP-Vav1G806A 
pMB65 pEGFP-C2 EGFP-Vav1Q817A 
pMB66 pEGFP-C2 EGFP-Vav1Q818A 
pMB67 pEGFP-C2 EGFP-Vav1Y826A 
  
 
Table S2 (continuation). 
 
Name 
 
Vector backbone Encoded protein 
pMB68 pEGFP-C2 EGFP-Vav1G827A 
pMB79 pEGFP-C2 EGFP-Vav1V837A 
pMB80 pEGFP-C2 EGFP-Vav1E838A 
pMB81 pEGFP-C2 EGFP-Vav1E839A 
pMB82 pEGFP-C2 EGFP-Vav1D840A 
pMB83 pEGFP-C2 EGFP-Vav1S842A 
pMB84 pEGFP-C2 EGFP-Vav1E843A 
pMB94 pEGFP-C2 EGFP-Vav1DFCmut 
pMB100 pEGFP-C2 EGFP-Vav1DFC-Rmut 
pMB101 pEGFP-C2 EGFP-Vav1YVEEDmut 
pMB104 pEGFP-C2 EGFP-Vav1DFC-R+YVEEDmut 
pMB111 pEGFP-C2 EGFP-Vav1D376A+DFC-Rmut 
pMB109 pEGFP-C2 EGFP-Vav1D376A+DFC-R+YVEEDmut 
pMB108 pGEX 6P-1 GST-CSH3DFC-Rmut 
pMB130 pGEX 6P-1 GST-CSH3YVEEDmut 
pMB131 pGEX 6P-1 GST-CSH3DFC-R+YVEEDmut 
pMB115 pGEX 6P-1 GST-SH3DFC-R+P833Lmut 
pMB141 pGEX 6P-1 GST-SH3P833L+YVEEDmut 
pMB142 pGEX 6P-1 GST-SH3DFC-Rmut+P833L+YVEEDmut 
pJRC64 pEF1-Myc-His A Vav1Y541F 
pMB13 pEF1-Myc-His A Vav1Y174F+Y541F 
pMB23 pEF1-Myc-His A Vav1Y541E 
pMB124 pEF1-Myc-His A Vav1Y174F+Y541E 
pJRC65 pEF1-Myc-His A Vav1Y544F 
pMB14 pEF1-Myc-His A Vav1Y174F+Y544F 
pMB24 pEF1-Myc-His A Vav1Y544E 
pMB31 pEF1-Myc-His A Vav1Y174F+Y544E 
pMB41 pGEX 6P-1 GST-CSH3Y836F 
pMB36 pGEX 6P-1 GST-CSH3Y836E 
pMB144 pEGFP-C2 EGFP-Vav1Y541F+Δ835-845 
pMB147 pEGFP-C2 EGFP-Vav1Y544F+Δ835-845 
  
Table S3.  List of primers. F, forward; R, reverse. 
 
Mutation 
 
Primer 
F 5’-GCA GAG GGG GAC GAG ATC TTC GAG GAC CTA ATG CGC TTG-3’ Y174F 
R 5’-CAA GCG CAT TAG GTC CTC GAA GAT CTC GTC CCC CTC TGC-3’ 
F 5’-CGG CCG GAT CGG CTG GTT CCC TTC TAA CTA TGT GGA GGA AG-3’ P833L 
R 5’-CTT CCT CCA CAT AGT TAG AAG GGA ACC AGC CGA TCC GGC CG-3’ 
F 5’-GGA ATA CTA TGG GAT CGC TGC TGC ACC TGG AGC-3’ AAAP R 5’-GCT CCA GGT GCA GCA GCG ATC CCA TAG TAT TCC-3’ 
F 5’-GTC GGC TGG TTT CTC TGT AAC AGA GTG C-3’ P651L R 5’-GCA CTC TGT TAC AGA GAA ACC AGC CGA C-3’ 
F 5’-GGG ACC TGG CAC AGT GCG TGG CCG CGG TCA AGA GGG ACA ATG AAA CC-3’ NEmut 
R 5’-GGT TTC ATT GTC CCT CTT GAC CGC GGC CAC GCA CTG TGC CAG GTC CC-3’ 
F 5’-CTG GCA CAG TGC GTG AAC GAG GCC GCG AGG GAC AAT GAA ACC CTA CGG-3’ VKmut 
R 5’-CCG TAG GGT TTC ATT GTC CCT CGC GGC CTC GTT CAC GCA CTG TGC CAG-3’ 
F 5’-GCA CAG TGC GTG AAC GAG GTC AAG GCG GCC AAT GAA ACC CTA CGG CAG ATC AC-3’ RDmut 
R 5’-GTG ATC TGC CGT AGG GTT TCA TTG GCC GCC TTG ACC TCG TTC ACG CAC TGT GC-3’ 
F 5’-GGG ACC TGG CAC AGT GCG TGG CCG CGG TCA AGG CGG CCA ATG AAA CC-3’ NE+RDmut 
R 5’-GGT TTC ATT GGC CGC CTT GAC CGC GGC CAC GCA CTG TGC CAG GTC CC-3’ 
F 5’-CTG GCA CAG TGC GTG GCC GCG GCC GCG GCG GCC AAT GAA ACC CTA CGG-3’ NEVKRDmut 
R 5’-CCG TAG GGT TTC ATT GGC CGC CGC GGC CGC GGC CAC GCA CTG TGC CAG-3’ 
F 5’-GGG ACA ATG AAA CCC TAC GGC AGA TCG CAA ACT TTC AGC TGT CCA TTG AGA AC-3’ T384A 
R 5’-GTT CTC AAT GGA CAG CTG AAA GTT TGC GAT CTG CCG TAG GGT TTC ATT GTC CC-3’ 
  
Table S3 (continuation). 
Mutation Primer 
F 5’-GGC AGA TCA CAA ACT TTC AGG CGT CCA TTG AGA ACC TGG ACC-3’  L388A 
R 5’-GGT CCA GGT TCT CAA TGG ACG CCT GAA AGT TTG TGA TCT GCC-3’ 
F 5’-GGC ACA GTG CGT GAA CGA GGC CAA GAG GGA CAA TGA AAC CCT AC-3’  V373A 
R 5’-GTA GGG TTT CAT TGT CCC TCT TGG CCT CGT TCA CGC ACT GTG CC-3’ 
F 5’-GGC ACA GTG CGT GAA CGA GGT CGC GAG GGA CAA TGA AAC CC-3’ K374A 
R 5’-GGG TTT CAT TGT CCC TCG CGA CCT CGT TCA CGC ACT GTG CC-3’ 
F 5’-CAG TGC GTG AAC GAG GTC AAG GCG GAC AAT GAA ACC CTA CGG-3’ R375A 
R 5’-CCG TAG GGT TTC ATT GTC CGC CTT GAC CTC GTT CAC GCA CTG-3’ 
F 5’-GTG AAC GAG GTC AAG AGG GCC AAT GAA ACC CTA CGG CAG-3’ D376A 
R 5’-CTG CCG TAG GGT TTC ATT GGC CCT CTT GAC CTC GTT CAC-3’ 
F 5’-GCA CTG CCA AAG CCC GCT ACG CCT TCT GTG CCC GGG ACA GGT C-3’ D792A 
R 5’- GAC CTG TCC CGG GCA CAG AAG GCG TAG CGG GCT TTG GCA GTG C -3’ 
F 5’- CTG CCA AAG CCC GCT ACG ACG CCT GTG CCC GGG ACA GGT CGG -3’ F793A 
R 5’- CCG ACC TGT CCC GGG CAC AGG CGT CGT AGC GGG CTT TGG CAG -3’ 
F 5’-CCA AAG CCC GCT ACG ACT TCG CTG CCC GGG ACA GGT CGG AAC-3’ C794A 
R 5’-GTT CCG ACC TGT CCC GGG CAG CGA AGT CGT AGC GGG CTT TGG-3’ 
F 5’-CGC TAC GAC TTC TGT GCC GCG GAC AGG TCG GAA CTG TCC C-3’ R796A 
R 5’-GGG ACA GTT CCG ACC TGT CCG CGG CAC AGA AGT CGT AGC G-3’ 
F 5’-GGA CAG GTC GGA ACT GTC CCT TGC GGA GGG TGA TAT CAT CAA GAT C-3’ K804A 
R 5’-GAT CTT GAT GAT ATC ACC CTC CGC AAG GGA CAG TTC CGA CCT GTC C-3’ 
  
Table S3 (continuation). 
Mutation Primer 
F 5’- CGG ATC GGC TGG TTC CCT TCT GCC TAT GTG GAG GAA GAC TAT TC -3’ N835A 
R 5’- GAA TAG TCT TCC TCC ACA TAG GCA GAA GGG AAC CAG CCG ATC CG -3’ 
F 5’- GTA TTT TGG CAC TGC CAA AGC CGC CTA CGA CTT CTG TGC CCG GGA C -3’ R790A 
R 5’- GTC CCG GGC ACA GAA GTC GTA GGC GGC TTT GGC AGT GCC AAA ATA C -3’ 
F 5’- GCA CTG CCA AAG CCC GCG CCG ACT TCT GTG CCC GGG -3’ Y791A 
R 5’- CCC GGG CAC AGA AGT CGG CGC GGG CTT TGG CAG TGC -3’ 
F 5’- CGC TAC GAC TTC TGT GCC CGG GCC AGG TCG GAA CTG TCC CTT AAG -3’ D797A 
R 5’- CTT AAG GGA CAG TTC CGA CCT GGC CCG GGC ACA GAA GTC GTA GCG -3’ 
F 5’- CTA CGA CTT CTG TGC CCG GGA CGC GTC GGA ACT GTC CCT TAA GGA G -3’ R798A 
R 5’- CTC CTT AAG GGA CAG TTC CGA CGC GTC CCG GGC ACA GAA GTC GTA G -3’ 
F 5’- GAC TTC TGT GCC CGG GAC AGG GCG GAA CTG TCC CTT AAG GAG G -3’ S799A 
R 5’- CCT CCT TAA GGG ACA GTT CCG CCC TGT CCC GGG CAC AGA AGT C -3’ 
F 5’- GTC GGA ACT GTC CCT TAA GGC GGG TGA TAT CAT CAA GAT CC -3’ E805A 
R 5’- GGA TCT TGA TGA TAT CAC CCG CCT TAA GGG ACA GTT CCG AC -3’ 
F 5’- GAA CTG TCC CTT AAG GAG CGT GAT ATC ATC AAG ATC C -3’ G806A 
R 5’- GGA TCT TGA TGA TAT CAC GCT CCT TAA GGG ACA GTT C -3’ 
F 5’- GAT CCT CAA TAA GAA GGG ACG GCA AGG CTG GTG GCG TGG GG -3’ Q817A 
R 5’- CCC CAC GCC ACC AGC CTT GCC GTC CCT TCT TAT TGA GGA TC -3’ 
F 5’- CTC AAT AAG AAG GGA CAG CGA GGC TGG TGG CGT GGG GAG -3’ Q818A 
R 5’- CTC CCC ACG CCA CCA GCC TCG CTG TCC CTT CTT ATT GAG -3’ 
  
Table S3 (continuation). 
 
Mutation 
 
Primer 
F 5’-CTG GTG GCG TGG GGA GAT CCG CGG CCG GAT CGG CTG GTT C-3’ Y826A 
R 5’-GAA CCA GCC GAT CCG GCC GCG GAT CTC CCC ACG CCA CCA G-3’ 
F 5’-CTG GTG GCG TGG GGA GAT CTA CCG CCG GAT CGG CTG GTT CCC TTC-3’ G827A 
R 5’-GAA GGG AAC CAG CCG ATC CGG CGG TAG ATC TCC CCA CGC CAC CAG-3’ 
F 5’-CGG CTG GTT CCC TTC TAA CTA TGC GGA GGA AGA CTA TTC CGA ATA TTG-3’ V837A 
R 5’-CAA TAT TCG GAA TAG TCT TCC TCC GCA TAG TTA GAA GGG AAC CAG CCG-3’ 
F 5’-CTG GTT CCC TTC TAA CTA TGT GGC GGA AGA CTA TTC CGA ATA TTG-3’ E838A 
R 5’-CAA TAT TCG GAA TAG TCT TCC GCC ACA TAG TTA GAA GGG AAC CAG-3’ 
F 5’-CCT TCT AAC TAT GTG GAG GCA GAC TAT TCC GAA TAT TGC-3’ E839A 
R 5’-GCA ATA TTC GGA ATA GTC TGC CTC CAC ATA GTT AGA AGG-3’ 
F 5’-CTT CTA ACT ATG TGG AGG AAG CCT ATT CCG AAT ATT GCT GAG C-3’ D840A 
R 5’-GCT CAG CAA TAT TCG GAA TAG GCT TCC TCC ACA TAG TTA GAA G-3’ 
F 5’-CTA TGT GGA GGA AGA CTA TGC CGA ATA TTG CTG AGC CTG-3’ S842A 
R 5’-CAG GCT CAG CAA TAT TCG GCA TAG TCT TCC TCC ACA TAG-3’ 
F 5’-GTG GAG GAA GAC TAT TCC GCA TAT TGC TGA GCC TGG TGC-3’ E843A 
R 5’-GCA CCA GGC TCA GCA ATA TGC GGA ATA GTC TTC CTC CAC-3’ 
F 5’-GCA CTG CCA AAG CCC GCT ACG CCG CCG CAG CCC GGG ACA GGT CGG AAC TG-3’ DFCmut 
R 5’-CAG TTC CGA CCT GTC CCG GGC TGC GGC GGC GTA GCG GGC TTT GGC AGT GC-3’ 
  
Table S3 (continuation). 
 
Mutation 
 
Primer 
F 5’-CGC TAC GCC GCC GCA GCC GCG GAC AGG TCG GAA CTG TCC C-3’	  DFC-Rmut 
R 5’-GGG ACA GTT CCG ACC TGT CCG CGG CTG CGG CGG CGT AGC G-3’	  
F 5’-CGG ATC GGC TGG TTC CCT TCT AAC GCA GCG GCG GCA GCC TAT TCC GAA TAT TG-3’ YVEEDmut 
R 5’-CAA TAT TCG GAA TAG GCT GCC GCC GCT GCG TTA GAA GGG AAC CAG CCG ATC CG-3’ 
F 5’-CGG ATC GGC TGG TTC CCT TCT AAC GCA GCG GCG GCA GCC TAT TCC GAA TAT TG-3’ P833L+YVE
EDmut R 5’-CAA TAT TCG GAA TAG GCT GCC GCC GCT GCG TTA GAA GGG AAC CAG CCG ATC CG-3’ 
F 5’-GGC ACA TTC TAC CAG GGA TTT CGC TGT TAC AGG TGC CGG-3’ Y541F 
R 5’-CCG GCA CCT GTA ACA GCG AAA TCC CTG GTA GAA TGT GCC-3’ 
F 5’-GGC ACA TTC TAC CAG GGA GAG CGC TGT TAC AGG TGC CGG-3’ Y541E 
R 5’-CCG GCA CCT GTA ACA GCG CTC TCC CTG GTA GAA TGT GCC-3’ 
F 5’-GGC ACA TTC TAC CAG TTT GAA CGC TGT TAC AGG-3’ Y544F R 5’-CCT GTA ACA GCG TTC AAA CTG GTA GAA TGT GCC-3’ 
F 5’-GGC ACA TTC TAC CAG GGA GAA CGC TGT TAC AGG-3’ Y544E R 5’-CCT GTA ACA GCG TTC TCC CTG GTA GAA TGT GCC-3’ 
F 5'-CGG CTG GTT CCC TTC TAA CTT TGT GGA GGA AGA CTA TTC CG-3' Y836F 
R 5'-CGG AAT AGT CTT CCT CCA CAA AGT TAG AAG GGA ACC AGC CG-3' 
F 5’-GGC TGG TTC CCT TCT AAC GAG GTG GAG GAA GAC TAT TCC-3’ Y836E 
R 5’-GGA ATA GTC TTC CTC CAC CTC GTT AGA AGG GAA CCA GCC-3’ 
 
 
